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Chapter 1 
 
CREATINE METABOLISM AND PLEIOTROPIC EFFECTS 
 
 
This chapter provides a review about creatine, including its biosynthesis and transport, as well as its 
metabolism and functions. An excursus on the creatine kinase isoforms and the importance of their different 
locations in subcellular sites will be described, as well as creatine and phosphocreatine effects as spatial and 
temporal buffers, and as metabolic regulators. Besides these roles, other creatine effects have been observed, 
suggesting a “pleiotropic” effect, which might be crucial in normal Central Nervous System development and 
function.  
 
1.1 Creatine biosynthesis 
Creatine (Cr, α-N-methylguanidino acetic acid) is a nitrogenous organic acid discovered in 1832 by 
Michel Eugène Chevreul, and chemically identified by Justus von Liebig in 1847. It can be taken up from the 
diet, especially from meat and fish, and endogenously synthesized in the liver, pancreas, kidneys, and brain. 
Endogenous synthesis involves the amino acids glycine, arginine and methionine, and two enzymes: 
arginine:glycine amidinotransferase (AGAT) and guanidinoacetate methyltransferase (GAMT). In the first 
step of Cr biosynthesis, AGAT transfers a guanidinic group from arginine to glycine, yielding guanidinoacetic 
acid (GAA) and ornithine. The second step, catalyzed by GAMT, consists in the transfer of a methyl group 
from S-adenosylmethionine (SAM) to convert GAA into Cr, also releasing S-adenosylhomocysteine (SAH) 
(Fig. 1). The first reaction occurs mainly in the kidney and pancreas, where elevated AGAT activity is found, 
while the second step is mainly located in the liver where there is elevated GAMT activity. Subsequently, Cr, 
about 1 g/d acquired from the diet and 1 g/d endogenously synthesized, is distributed through the blood to 
organs characterized by high and fluctuating energy demands such as the muscles and brain. Here, a transporter 
Na+-Cl-dependent, CT1, allows Cr transit into the cells (Salomons and Wyss 2007). CT1 is the most expressed 
transporter, although another isoform, CT2, has been found primarily in the testes. 95% of Cr stores are located 
in the skeletal muscle, while the remaining 5% is distributed in the brain, liver, kidneys, and testes. It is possible 
to find Cr in two forms: the phosphorylated form (Phosphocreatine) which represents 60% of the stores, and 
the free form representing the other 40%. Finally, the Cr pool in an average 70 kg young male is around 120-
140 g, however it varies between individuals depending on the skeletal muscle fiber type and quantity of 
muscle mass (Cooper et al. 2012).   
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Once inside the cell, Cr is phosphorylated through the reversible reaction catalyzed by creatine kinase 
(CK): Phosphocreatine (PCr) + MgADP + H+ ↔ Creatine (Cr) + MgATP and acts primarily as a temporal and 
spatial ATP buffer. In particular, Cr is phosphorylated to generate a pool of PCr that could be used during 
energy demand to yield ATP from ADP. Then, Cr and PCr are subject to a spontaneous, non-enzymatic 
conversion to creatinine and phosphocreatinine, which are excreted through urine. This conversion amounts 
to a significant drop in the cellular Cr/PCr pool, with a constant daily turnover of about 1.5-2% of Cr (Salomons 
and Wyss 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Schematic representation of creatine metabolism: creatine synthesis and creatine kinase (CK) 
reaction. Creatine synthesis is a two-step process involving two enzymes: L-arginine:glycine 
amidinotransferase (AGAT) and N-guanidinoacetate methyltransferase (GAMT). AGAT using 
arginine and glycine forms guanidinoacetic acid, which is the substrate for GAMT reaction to produce 
creatine. Once inside the cell, creatine is subject to the CK reaction: CK catalyzes the phosphorylation 
or dephosphorylation of creatine and phosphocreatine, respectively, during ATP generation and use. 
3 
 
1.2 Creatine transporters 
The physiological importance of Cr transport was first recognized with respect to muscle where high 
concentrations of PCr are demanded for muscle contractions. Cr biosynthesis occurs mostly in other organs, 
thus about 2 g/day of Cr must be taken up by skeletal muscle to compensate for losses due to irreversible 
conversion to creatinine. A specific plasma membrane Cr transporter, CT1 (also called SLC6A8, CRT, CRTR, 
CreaT), is required for the cellular uptake of Cr. 
CT is a member of solute carrier family 6 (SLC6), a large family of membrane transporters that mediate 
the translocation of a range of solutes across plasma membranes, through the co-transport of sodium and 
chloride down their electrochemical gradients. Regarding this solute carrier family, the transporters for 
neurotransmitters such as γ-aminobutyric acid (GABA), norepinephrine, and subsequently, dopamine and 
serotonin were the first to be discovered. Later, transporters for solutes like Cr were also included in this family 
(Salomons and Wyss 2007). Another transporter, the monocarboxylate transporter 12 (MCT12, also called 
SLC6A12), has recently been shown to be involved in both the uptake and efflux of Cr. This transporter is also 
a member of solute carrier family 6 and is predominantly found in the kidneys and retina (Abplanalp et al. 
2013). 
CT allows Cr to cross the membrane in a saturable, sodium/chloride-dependent and highly specific 
manner. In more detail, the transport of Cr through the CT is saturable because of Cr Km and Cr concentrations 
in plasma. For example, rat and human brain CTs are characterized by an apparent Km of 29 µM and 15 µM 
(Saltarelli et al. 1996, Sora et al. 1994), respectively, and these Km values are 10-40 fold lower than serum Cr 
concentration (528 µM in rats and 58 µM in humans) (Marescau et al. 1986). Therefore, it is obvious from the 
concentration of Cr in plasma that CTs work close to saturation, suggesting that the number of transporters in 
the cell membrane may limit Cr storage. Moreover, research has shown that CT is Na+-dependent, underlying 
that other cations such as lithium, choline or N-methylglucamine cannot replace sodium. In addition, CT is 
also Cl−-dependent. This is an important consideration as not all SLC6 transporters are dependent on chloride. 
It appears that CT exchange 2 Na+ and 1 Cl- for each Cr molecule. Finally, CTs are highly specific for Cr and 
neither creatinine nor phosphocreatine are substrates. The key features for substrate specificity are a carboxyl 
group and a guanidino group, separated by no more than 2–3 carbon atoms (Salomons and Wyss 2007).  
The fundamental feature of CT and other transporters is how they are able to recognize their substrates 
and translocate them across the membrane. The structure of a member of the SLC6 transporter family was first 
provided through the study of the crystal structure of a bacterial leucine transporter (LeuTAa) (Yamashita et al. 
2005). LeuTAa is Na+-dependent, but not Cl--dependent, thus its structure could not provide information on the 
Cl− binding site. The structure of LeuTAa supports the two gate theory for transporters: exposure of the binding 
site to the outside of the cell enables the substrate to bind; closure of the external gate traps the substrate within 
the membrane; opening of an internal gate allows the release of the substrate into the cell. Although LeuTAa is 
only 20-25% identical to the mammalian SLC6 transporters, the conservation of residues in SLC6 transporters 
at key positions and the topology of LeuTAa make this bacterial SLC6 homologue a valuable model for 
mammalian CT and other SLC6 transporters (Salomons and Wyss 2007).  
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CT is important for normal brain development function as mutations in the CT gene (SLC6A8) result 
in X-linked mental retardation, associated with cerebral creatine deficiency, severe speech and language delay, 
epilepsy, autistic behavior, and increased urinary Cr/creatinine ratio (Salomons and Wyss 2007). Moreover, 
studies investigating CT structure and function are essential to understand the optimal Cr supplementation that 
may efficiently increase the PCr pool in the cell. 
 
1.3 Creatine kinase  
The creatine kinase enzyme (CK) was discovered by Lohmann in 1934 and the CK reaction was found 
in 1936, but its physiological importance was understood only later. In the last few decades, discussion has 
arisen concerning the role of the Cr/CK system in the distribution and intracellular transport of high-energy 
phosphates, the importance of which is related to cellular diffusion distances. The presence and the localization 
of different CK isoforms at various ATP sources and sinks provide the elements for a spatial and temporal 
ATP buffering and energy transport pathway, the so-called CK shuttle or PCr circuit. In 1966, Bessman and 
Fonyo were the first to propose this shuttle concept, which implicates cellular compartmentation of the 
reactants of the CK reaction (Salomons and Wyss 2007).  
In higher organisms there are three CK isoforms, cytoplasmic, mitochondrial and flagellar (Cyt-, Mt- 
and FlgCKs), each targeted to different micro-compartments in the cell. They are found in different forms, in 
particular, CytCKs are dimers while typical MtCKs exist as both dimers and octamers, with the latter 
predominating under physiological conditions. FlgCKs are “contiguous trimers” consisting of three fused, 
complete CK domains in a single polypeptide chain. Furthermore, four CK genes coding for five different 
isoenzymes have been identified. Two genes for CytCK encode for muscle (M-CK) and brain (B-CK) 
isoforms, which assemble into active homo-dimeric (MM-CK, BB-CK) and hetero-dimeric (MB-CK) enzymes 
in the cytosol. MM-CK is expressed at high levels in muscle, representing between 85% and 95% of total CK 
activity. MB-CK is a transitional isoform, which is present in immature stages of skeletal muscle and, in low 
amounts in the heart. BB-CK is expressed at high levels in the brain and various other tissues in adult mice. 
Expression of the other isoenzymes of CK, ubiquitous (uMt-CK) and sarcomeric mitochondrial CK (sMt-CK), 
is also cell-type dependent. uMt-CK is mostly co-expressed with BB-CK (Salomons and Wyss 2007). Recent 
studies indicate that in the brain, BB-CK is preferentially expressed in astrocytes and inhibitory neurons, while 
mitochondrial CK seems to be restricted primarily to neurons (Tachikawa et al. 2004). The expression of sMt-
CK is confined to muscle. uMt-CK and sMt-CK isoforms occur as dimeric or octameric enzymes and reside 
between the inner and outer membranes of mitochondria. Mitochondrial isoforms of CK were discovered in 
Klingenberg’s laboratory in 1964, shortly after the discovery of the cytosolic MM- and BB-CK isoforms.  
In summary, mitochondrial and cytosolic CKs differ in regard to their organellar locations, and their 
form, dimeric and mainly octameric, respectively, as well as for the fact that the octameric mitochondrial CK 
behaves as a peripheral membrane protein, interacting with different protein and lipid components of the 
mitochondrial membranes (Salomon and Wyss 2007). Each isoform has a specific role as mitochondrial CKs 
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consume ATP to produce PCr to export it to the cytoplasm, while cytoplasmic CKs control energy demand 
through PCr consumption for local ATP production at subcellular sites of high-energy demand 
(Hanna‑El‑Daher and Braissant 2016).  
 
1.4 The Creatine/Phosphocreatine/Creatine Kinase system and pleiotropic effects of Creatine 
Cr has pleiotropic effects mainly through the functions of the enzyme CK and its high-energy product 
PCr. Many studies have demonstrated molecular, cellular, organ and somatic effects of the Cr/PCr/CK system, 
in particular for cells and organs with high and intermittent energy demands such as skeletal, cardiac and 
smooth muscle, the kidneys, the Central Nervous System (CNS) and neuronal cells, retina photoreceptor cells, 
spermatozoa and sensory hair cells of the inner ear. The Cr/PCr/CK system acts primarily as an immediately 
available temporal energy buffer, a spatial energy buffer or intracellular energy transport system (the 
Cr/PCr/CK energy shuttle or circuit), and as a metabolic regulator. Indeed, the Cr/PCr/CK energy circuit allows 
the shuttling of high-energy phosphates between sites of ATP production (glycolysis and mitochondrial 
oxidative phosphorylation) and sites of ATP utilization (ATPases), counteracting diffusion limitations in cells 
(Wallimann et al. 2011). 
High intracellular ATP concentration and ATP hydrolysis would increase the ADP, Pi and H+ content, 
leading to acidification of the cytosol. This would negatively interfere with ATPases activity such as the 
ATPase related with myofibrillar acto-myosin, and consequently, muscle contraction, and many other cellular 
processes. The phosphagens system, including PCr together with its corresponding kinase, CK, solves this 
problem and allows for the immediate replenishment of ATP stores. For example, during muscle contraction 
the CK reaction uses PCr to resynthesize ATP, removing ADP and H+ as products of hydrolysis of ATP, so 
that the net product of ATPases combined with the CK reaction is liberation of Pi as a metabolic signal. Thus, 
CK acts not only as an energy buffer but also as a metabolic regulator (Wallimann et al. 2011). 
The presence of different CK isoforms and their specific subcellular locations are the most relevant 
features of the Cr/PCr/CK system and the associated cellular functions. The Cr/PCr/CK shuttle exerts its spatial 
energy buffering role through functionally coupled, subcellular CK micro-compartments located where ATP 
is produced and where it is consumed. In fact, CK is the enzyme of a reversible reaction, leading either to the 
increase of the PCr pool or the re-synthesis of ATP, depending on the subcellular location and needs. Studies 
have shown important features of structure/function relationships and molecular physiology of CK that has 
allowed an understanding of the Cr/PCr/CK system and its eminent physiological role (Wallimann et al. 2011).  
 
1.4.1 Temporal and spatial energy buffering role 
The temporal and spatial energy buffering function of the Cr/PCr/CK shuttle is represented in Fig. 2. 
Cr acquired from the diet or via endogenous synthesis may cross the membrane through CTs. Inside the cell, 
Cr is converted into PCr through the action of cytosolic CKs (CK-c, (Fig. 2-C)), CKs coupled to glycolysis 
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(CK-g, (Fig. 2-B)) or MtCKs coupled to oxidative phosphorylation (MtCK, (Fig 2-A)). In a resting cell, the 
total Cr pool is subdivided in approximately two-thirds [PCr] and one-third [Cr] and in a high ATP/ADP ratio. 
Thus, the functional micro-compartments, specifically the glycogenolytic/glycolytic CK-g 
microcompartments (Fig. 2-B) and the MtCK microcompartment connected to oxidative phosphorylation and 
energy channeling reactions inside the mitochondria (Fig. 2-A), represent the ATP/PCr-generating side of the 
circuit (Schlattner et al. 2006). The result of the coupling of CK to glycolytic enzymes and adenine nucleotide 
translocator (ANT) in the mitochondria is the generation of a large PCr pool (up to 30 mM) available for 
temporal or spatial energy buffering.  
 
 
 
Other CKs are specifically associated with ATPases that hydrolyze ATP (CK-a, (Fig. 2-D)), such as 
the myofibrillar acto-myosin ATPase, the SR Ca2+-ATPase, and the plasma membrane Na+/K+-ATPase. These 
functional micro-compartments, where CK regenerates ATP by using the PCr stores, represent the ATP/PCr-
consuming side of the CK/PCr system (Fig. 2-D). In details, the MtCK isoform is specifically located in the 
mitochondrial intermembrane space with preferential access to ATP generated by oxidative phosphorylation 
 
Fig. 2. The temporal and spatial energy buffering of the CK/PCr system. Creatine enters the cells trough Cr transporters 
(CTs). Inside the cell, PCr, Cr and ATP/ADP are balanced by a soluble fraction of cytosolic CK isoforms (CK-c, see 
(C)). Another portion of cytosolic CK (CK-g, see (B)) is specifically associated with glycolytic enzymes (G), which 
accepts glycolytic ATP, while mitochondrial CK isoforms (MtCK, see (A)) is connected to adenine nucleotide 
translocator (ANT), thus accepting ATP exported from the mitochondrion and generated by oxidative phosphorylation 
(OP). The PCr generated creates a pool of PCr up to 30 mM, which is available for temporal or spatial energy buffering. 
Another portion of cytosolic CK (CK-a, see (D)) specifically linked with subcellular sites of ATP utilization also forms 
tightly coupled microcompartments that regenerate the ATP utilized by the ATPase. The CK/PCr energy shuttle, trough 
highly diffusible PCr and Cr, connects subcellular sites of ATP production (glycolysis and mitochondrial oxidative 
phosphorylation) with subcellular sites of ATP utilization (ATPases).  
 
Figure adapted from Wallimann et al. 2011 
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via ANT of the mitochondrial inner membrane. Thus, the ATP produced by mitochondria, is phosphorylated 
by MtCKs into PCr, which then moves to the cytosol. The ATP generation in this site leads to the refill of PCr 
pool in oxidative tissues, such as in the muscle after contraction.  
The cytosolic PCr store is built up by CK using ATP predominantly from oxidative phosphorylation 
(Fig. 2-A) as in the heart, or from glycolysis (Fig.2-B) plus oxidative phosphorylation (Fig.2-A) as in skeletal 
muscle. PCr is then used to buffer global cytosolic (Fig. 2-C) and local (Fig.2D) ATP/ADP ratios. This 
represents the temporal buffer function of the system. The importance of the spatial and temporal energy 
buffering is evident in cells that are polarized, such as spermatozoa, retina photoreceptor cells, and sensory 
hair cells located in the inner ear, where the Cr/PCr/CK shuttle solves the problem of the limited diffusion 
capability in long distances of ATP and ADP (Wallimann et al. 2011).  
 
1.4.2 Cytosolic Creatine Kinase associated with glycolysis function 
Cytosolic CKs are coupled with glycolytic enzymes (Fig. 2-B) that are involved in ATP synthesis, 
such as pyruvate kinase (PK), or with the principal regulatory enzyme of glycolysis, phosphofructokinase 
(PFK), which is regulated through a negative feedback mechanism by ATP increase. The CK-PFK interaction 
depends on pH and it is stronger at lower pH than at neutrality. This feature is physiologically relevant because 
during muscle contraction and concomitant glycolysis the intracellular pH may rapidly decrease. Thus, the 
localization of CKs in this site is crucial for two reasons: (a) through removing glycolytic ATP from this 
compartment, CK prevents the inhibition of glycolysis by negative feedback regulation via ATP accumulation, 
and (b) through reducing the depletion of the PCr pool during contraction using the glycolytic ATP (Wallimann 
et al. 2007).  
 
1.4.3 Mitochondrial Creatine Kinase function 
1.4.3.1 Metabolite channeling in the mtCK microcompartment 
MtCKs are first assembled into dimers that rapidly associate into octamers, which is the favored form. 
The mtCK octamers then directly bind to acidic phospholipids in the mitochondrial membranes (Fig. 3), 
preferentially to cardiolipin of the inner mitochondrial membrane (Schlattner et al. 2004), and in a calcium 
dependent way directly to VDAC (Schlattner et al. 2001). ANT and MtCK both have affinity for cardiolipin, 
and are thus located in cardiolipin patches, where they may functionally interact. MtCK is situated in two sites 
of the mitochondria: (a) in the so-called mitochondrial contact sites (Fig. 3), where MtCK binds both to the 
inner and outer membrane and it functionally connected with ANT and VDAC and (b) in the cristae (not 
shown) connected with inner membrane and ANT only. In the figure 3, black arrows represent the preferred 
or exclusive substrate and product fluxes. 
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According to this representation, ATP synthesized by oxidative phosphorylation through the F0F1-
ATPase can cross the inner membrane through ANT in exchange for ADP. This ATP may either move to the 
cytosol directly via the outer membrane VDAC or used by MtCK to phosphorylate Cr, yielding PCr that exit 
the mitochondrion via VDAC. Subsequently, ADP generated from the MtCK reaction is accepted by ANT and 
immediately transported back into the matrix to be re-phosphorylated. In cristae, only ATP/ADP transfer is 
promoted through direct channeling to the MtCK active site, while Cr and PCr must diffuse along the cristae 
space to reach VDAC (not shown; Schlattner et al. 2006; Wallimann et al. 2007). 
 
Functional linking of ANT to MtCK leads to a saturation of MtCK with ATP released by ANT, and 
simultaneously to a locally high ATP/ADP ratio in the proximity of MtCK. Together with cytosolic Cr, 
crossing the outer membrane through VDAC, these conditions promote the generation of PCr from ATP by 
 
Fig. 3. Mitochondrial MtCK functions for high-energy metabolite channeling. In cells depended on oxidative 
metabolism, respiration (green arrow), ATP generation and ATP export through the inner membrane of the 
mitochondrion via adenine nucleotide transporter (ANT) are tightly coupled to phosphorylation of ATP into PCr 
through MtCK and transfer of PCr into the cytosol through the voltage-dependent anion channel (VDAC) in the 
outer membrane (black arrows). Creatine stimulates respiration by favoring constant provision of ADP to the matrix 
(black arrows), that also decreases ROS/RNS generation in the mitochondrion (red arrows) and inhibits 
mitochondrial permeability transition. The tight coupling of substrate and product fluxes (black arrows) allows the 
so-called channeling of ‘‘high-energy’’ metabolites, with PCr being the one released into the cytosol, and ATP/ADP 
being mainly recycled within the mitochondrion.  
 
Figure adapted from Wallimann et al. 2011 
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MtCK without losing energy content. All these reactions together are an instructive example of functional 
coupling and metabolite channeling. The active ATP/ADP transfer allowed by MtCK promotes ATP synthesis 
by the F0F1-ATPases and, thus, proper functioning of the respiratory chain, preventing the superoxide and 
reactive oxygen species (ROS) levels increasing (Schlattner et al. 2011). The intricate functional coupling of 
MtCK to the ANT, that leads to a saturation of the ANT on the outer site of the inner membrane with ADP, 
which then is transported back into the matrix to be re-phosphorylated by the F0F1-ATPase, efficiently connects 
substrate oxidation to ATP synthesis. This complex functional coupling, by avoiding futile electron transfer, 
would potentially also lower the production of free oxygen radicals (ROS). In fact, mitochondrial respiration 
in the presence of Cr needs low ADP concentration (µM) to be fully stimulated, while lacking of Cr and 
relatively high concentration of ADP (mM) are needed for a comparable respiratory rate. This important 
phenomenon is called “creatine-stimulated respiration”.  
Finally, Cr shows an indirect antioxidant effect by significantly reducing the ROS production in 
mitochondria, as well as elevating and preserving the mitochondrial membrane potential (Meyer et al. 2006). 
These and other Cr effects that go beyond cell bioenergetics may represent the basis for the interesting 
neuroprotective role that has been discovered recently (Andres et al. 2008).  
 
1.4.3.2 MtCK and mitochondrial membranes 
Both mitochondrial isoforms of CK, sMt-CK and uMt-CK octamers, are associated with the 
phospholipids of the mitochondrial membranes, in particular cardiolipin. The capacity of MtCK to bind to and 
cross-link the inner and outer membranes explains the contact site formation between the two membranes and 
the resulting mechanical stabilization of mitochondria. Furthermore, recent studies have shown that MtCK, 
once bound to cardiolipin containing membrane vesicles, is able to create cardiolipin molecules clusters around 
its molecular surface (Epand et al. 2007b) and, if cross-linked to another membrane vesicle, MtCK is able to 
facilitate lipid exchange between the inner and outer membranes (Epand et al. 2007a). This might be important 
for the structure and physiology of these membrane contact sites and the pre-apoptotic process of mitochondrial 
permeability transition pore (MPTP) function.  
As previously mentioned, MtCK is located in two strategically important sites: in the intermembrane 
and the cristae space. In the periphery of mitochondria, MtCK is part of a protein complex that is included in 
the so-called MPTP complex. Although the molecular structure of the pore has not been clarified, it appears 
to involve ANT-1 isoform, VDAC and MtCK. MPTP opening is an early event in apoptosis, leading to 
swelling of mitochondria and the release of apoptosis-inducing factors that can be initiated by elevation of 
extra-mitochondrial [Ca2+] (Azzolin et al. 2010). Experiments in mice in which MtCK is absent or 
overexpressed have shown inducing or protection from apoptotic events, respectively. In these studies, Cr is 
comparable to antiapoptotic agents showing the role of Cr not only in stimulating mitochondrial respiration, 
but also in preventing apoptosis beginning in the mitochondria (Brdiczka et al. 2006). This might explain some 
of the cell-related protective effects observed with Cr supplementation against hypoxia, liver toxins and tumor 
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necrosis factor-induced apoptosis. Moreover, PCr is able to bind to and protect biological membranes (Saks et 
al. 1996; Tokarska-Schlattner et al. 2003, 2005), and this is probably also true for the PCr produced by MtCK 
in mitochondria that bind to mitochondrial membranes and stabilize against swelling. Thus, MtCK together 
with Cr seems to exert cell protection not only through improving cellular energetics, but also by energy-
independent effects that also prevent and reduce apoptosis. 
 
1.5 Creatine and Central Nervous System 
The brain, which constitutes only about 2% of body mass, may account for up to 20% of total energy 
consumption. Thus, a high rate of ATP synthesis is necessary to maintain normal Central and Peripheral 
Nervous System function, including the electrical membrane potentials, ions gradients, Ca2+ homeostasis, and 
signaling activities (Braissant et al. 2010). In this scenario, the Cr/PCr/CK system plays an important role 
during rapid changes in ATP demands that occur for physiological activities of neurons, in particular through 
functionally coupling sites where ATP is generated and where it is consumed. In fact, the diffusion distances 
may be longer in neurons, and sites of high-energy consumption are often localized at remote locations from 
the soma, i.e., synapses. The importance of this energy buffer system in energy metabolism (Fig. 4) is evident 
in the brain where Cr is depleted, which is characterized by disruption of neuronal functions such as loss of 
hippocampal mossy fiber connection (Zandt et al. 2004), and changes in mitochondrial structure showing 
intramitochondrial uMt-CK-rich inclusion bodies (Wyss and Wallimann 1994). This last feature is typical for 
several clinical diseases, such as encephalomyopathies and mitochondrial myopathies.  
The importance of the Cr/PCr/CK system is also demonstrated by experiments using CK knockout 
mice or through depletion of brain Cr using pharmacological agents, where structural modifications as well as 
cognitive and behavioral aspects are seriously affected. In humans, Cr deficiency syndromes, involving either 
its biosynthesis or transport, have been recently discovered. Patients suffering from these disease show a lack 
of cerebral Cr, and exhibit multiple and critical neurological symptoms, such as developmental and speech 
delay, epileptic seizures, autism and severe mental retardation. This evidence suggests a significant 
physiological relevance of Cr/PCr/CK system for normal brain function (Andres et al. 2008). It is important to 
note that the CNS synthesizes its own Cr and low amounts of Cr is supplied from the periphery due to the 
limited permeability of the blood-brain barrier, as shown in detail in next chapters. Finally, in the brain, the 
Cr/PCr/CK system shows some peculiarities, with several studies on the variable expression of BB-CK and 
uMt-CK isoforms in glial and neuronal cells demonstrating close metabolic collaboration between these cell 
types for brain energetics (Kasischke et al. 2004). In fact, Cr through the CK reaction has been proposed to 
play the metabolic role in an intricate neuron-glial shuttle (Tachikawa et al. 2004). 
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The effect of Cr on the CNS goes beyond a role in cellular energy metabolism and in enhancing the 
cellular energy status. Indeed, recent findings have shown that Cr acts also as a direct antiapoptotic and 
antioxidant molecule, assuming additional importance in CNS functions. As a direct antiapoptotic molecule, 
as mentioned previously, Cr together with the action of uMt-CK in mitochondria prevents MPTP opening, an 
early event in apoptosis (Dolder et al. 2003). Furthermore, Cr supplementation has shown antioxidant effects 
through a mechanism involving a direct scavenging of ROS (Sestili et al. 2006), or by reducing the production 
of ROS generated by mitochondrion. This reducing of ROS production is an indirect effect achieved through 
the stimulation of mitochondrial respiration by Cr (Kay et al. 2000) that allows an efficient recycling of ADP 
inside mitochondria by uMt-CK, leading to tight coupling of mitochondrial respiration with ATP synthesis 
and suppression of ROS formation (Meyer et al. 2006). Protective effects of Cr were shown also against UV 
stress in keratinocytes and on human skin (Lenz et al. 2005). Moreover, it has been found that Cr normalizes 
mutagenesis of mitochondrial DNA and its functional consequences produced by UV irradiation of skin cells 
 
Fig. 4. Creatine functions in the Central Nervous System. (1) Creatine allows ATP regeneration and high-
energy phosphate shuttling through the Cr/PCr/CK system, and it is linked to basic cellular functions, 
namely maintaining membrane potential, ions gradients, Ca2+ homeostasis and, as a consequence, plays a 
role in cytoprotection as well as axonal and dendritic elongation. (2) Creatine is suggested to play a role in 
neurotransmission as it can be synthesized in neurons, released in an action potential-dependent manner, 
and it is a partial agonist of postsynaptic GABAA-R. Moreover, CT is expressed in the presynaptic element, 
probably for re-uptake and recycling of creatine. (3) Creatine represents one of the main CNS osmolytes 
(Cr efflux in hypo-osmotic conditions, and Cr taken up in hyper-osmotic conditions).  
 
Figure adapted from Hanna-El-Daher and Braissant 2016. 
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(Berneburg at al. 2005). This evidence denotes the role of Cr in preventing and reducing the generation of ROS 
that may cause cell damage and inactivation of CK, and through this effect Cr may have important role also in 
CNS function and protection. In fact, recent experiments in vivo and in vitro, using rat brains and CNS cells 
respectively, have demonstrated the antioxidant role of Cr in the CNS (Ireland et al. 2011; Sartini et al. 2012). 
An interesting study has shown a neuroprotective role of Cr through improved reperfusion rather than 
changes in the bioenergetics status in a mouse model of stroke (Prass et al. 2007), and in in vivo and in vitro 
rodent models of ischemia/anoxia, Cr perfusion before ischemia/anoxia reduced the volume of damaged brain 
tissue and led to neurological improvement (Hanna-El-Daher and Braissant 2016). Cr was also proposed as 
neuroprotective for several neurodegenerative disease such as Parkinson’s or Huntington’s disease (Lensman 
et al. 2006; Beal 2011; Cunha et al. 2014), however, the first therapeutic Cr supplementation trials appeared 
rather disappointing. This is probably due to the limited Blood-Brain barrier (BBB) permeability for Cr, and 
suggests to find new ways to facilitate Cr uptake by CNS. Finally, the Cr/PCr/CK system is essential during 
brain development to provide enough ATP for growing axons and dendrites at their growth cone extremities, 
and Cr was found to have pro-differentiation/trophic actions on maturing neuroblasts, suggesting an 
importance also in CNS development (Sartini et al. 2012). 
In recent years, several studies have suggested that Cr may play roles in the brain neurotransmission 
systems (Fig.4). In vivo and in vitro studies have demonstrated that Cr is able to act on GABAergic neurons 
as partial agonists of post-synaptic GABAA but not GABAB-receptors (Koga et al. 2005). Moreover, Cr was 
shown to be released in an action-potential dependent manner within organotypic cultures of rat brain slices, 
while synaptosomes prepared from the brain of young and adult rats were able to take up Cr (Almeida et al. 
2006; Peral et al. 2010). This strongly indicates that Cr may even act as a true neurotransmitter, involving a 
recapture/recycling system through CT expression in axonal terminals (van de Kamp et al. 2013). Finally, Cr 
may also act as an osmolyte and was found to protect cells from hyper-osmotic shock in vitro (Alfieri et al. 
2006) and in vivo (Bothwell et al. 2002; Braissant et al. 2011), suggesting Cr as one of the main brain cell 
osmolytes.  
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Chapter 2 
 
CREATINE SUPPLEMENTATION  
 
 
An excursion on creatine supplementation will be provided in this chapter. First, early studies about 
creatine supplementation as an ergogenic aid in sport will be reported. Then, recently, because of its 
pleiotropic properties, including antiapoptotic, antiexcitotoxic, antioxidant, and neuroprotective effects, 
creatine supplementation has also been investigated in the clinical field. Therefore, the focus in the second 
part of the chapter will be on creatine administration in neurodegenerative diseases, such as Alzheimer’s 
disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis, and Huntington’s disease, and in inborn errors 
of metabolism, namely mitochondrial encephalomyopathies, hyperammonemia, and cerebral creatine 
deficiency syndromes. The latter focus represents important diseases to investigate and clarify the importance 
of creatine on brain function and development. If creatine were so fundamental for Central Nervous System 
development, supplementation would be important during pregnancy to prevent and treat hypoxic-ischemic 
brain injury as long as it is safe. Thus, in the last part of this chapter, the safety of creatine supplementation 
will be addressed. 
 
2.1 Creatine supplementation in sport 
Cr is mostly known as an ergogenic aid in sport. Cr supplementation increases the content of Cr in 
muscle tissue. Muscle Cr uptake appears to be positive correlated with exercise performance, because it 
enables a more rapid ATP re-synthesis, especially between resistance training sets. Cr supplementation 
combined with heavy resistance training produces a significant increase in physical performance, namely in 
maximum (1RM) or endurance strength, as well as in fat free mass, and muscle morphology. However, it 
should be clarified that there are some contradictory studies that show no increase in exercise performance, 
although, some of these have not used an efficient Cr supplementation protocol or have recruited more non-
responders (Cooper et al. 2012). Furthermore, studies have shown that Cr supplementation may enhance 
recovery after high intensity exercise, as well as improving injury prevention, thermoregulation, 
rehabilitation, and concussion and spinal cord neuroprotection.    
The most common form of Cr used in studies is creatine monohydrate (CM), with the most effective 
supplementation protocol consisting of 5 g of CM (or about 0.3 g/kg body weight) four times daily for 5-7 
days. This supplementation protocol may enhance muscle Cr and PCr by 20-40%, considering that in a 
normal diet muscle Cr stores are already 60-80% saturated. After this supplementation-loading period leading 
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the muscle Cr pool to be fully saturated, a supplementation-maintaining period by ingesting 3–5 g/day is 
commonly used to preserve Cr stores. The concomitant carbohydrate or carbohydrate and protein together 
with CM have been demonstrated to be more effective in Cr retention. An ingestion of 3 g/day of CM for 28 
days is also generally used in the literature. However, through using this method it is possible that the muscle 
Cr pool will increase only gradually in comparison to the more rapid loading method. This would result in a 
lengthening of the time necessary for Cr stores to be saturated, and in a reduced effect on exercise 
performance and training adaptations. Once muscle Cr stores are elevated, it usually takes 4–6 weeks for 
them to return to baseline. Furthermore, muscle Cr level after the end of supplementation does not fall below 
baseline, suggesting that potential for long-term suppression of endogenous Cr synthesis does not seem to 
occur (Kreider et al. 2017).  
Cr supplementation plays its ergogenic role mainly through optimizing training adaptations in 
power/strength athletes or by reducing the recovery time in sprinters. Depending on the increase in muscle 
PCr, athletes show improvements in high intensity and repetitive exercise by 10-20% after Cr loading (Kreider 
et al. 2003). These ergogenic effects can be evident in adolescents, young adults and old individuals, as well 
as in both men and women, although with different magnitudes. Recently, there is a growing amount of 
literature that has investigated the long-term effects of Cr supplementation, in particular examining the muscle 
mechanisms affected, such as satellite cell proliferation, myogenic transcription factors and insulin-like growth 
factor-1 signaling, suggesting a role of Cr supplementation in muscle anabolism (Cooper et al. 2012). 
 
2.1.1 Resistance exercise 
In young healthy males supplemented with CM and trained using resistance exercise, a reduction was 
found in myostatin serum level, which is a muscle growth inhibitor (Saremi et al. 2010).  Combined Cr, protein, 
and carbohydrate supplementation together with heavy resistance training improved 1RM, lean body mass, 
fiber cross sectional area and contractile proteins in trained young males (Cribb et al. 2007). This study was 
the first to show such improvements in body composition at the cellular and sub cellular level in resistance 
trained participants due to Cr supplementation. Another study found that soon after the Cr loading period (5 
days) there was an increase of  250%, 45% and 70% for collagen mRNA, glucose transporter 4 (GLUT4) and 
Myosin heavy chain IIA, respectively (Deldicque et al. 2008). The researchers suggested that Cr in addition to 
a single session of resistance exercise might favor an anabolic environment by inducing changes in gene 
expression after only 5 days of supplementation. Cr supplementation in addition to heavy resistance training 
also increases muscle insulin like growth factor (IGF-1) concentration (Burke et al. 2008). Thus, despite some 
controversial results, it appears that Cr supplementation combined with heavy resistance training amplifies 
performance improvements in maximum and endurance strength as well as in muscle hypertrophy, stimulating 
production of muscle IGF-I and muscle protein synthesis (Cooper et al. 2012). 
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2.1.2 Anaerobic exercise 
Regarding the role of Cr supplementation in predominantly anaerobic exercise, Cr increases 
neuromuscular performance in short duration, anaerobic, intermittent exercises. These exercises could be 
divided into activities lasting less than 30 seconds that primarily use the ATP/PCr energy system, and anaerobic 
endurance exercise lasting from 30-150 seconds, in which the primary energy system is glycolysis. Exercises 
less than 30 seconds in duration have shown enhancements mainly in the number of repetitions, but also in the 
total work carried out, weight lifted, time, force production, cycle ergometer revolutions per minute and power. 
The mechanism responsible could be related both to an increased Cr pool, allowing rapid and greater ATP 
synthesis, and an enhanced reuptake of Ca2+ into the sarcoplasmic reticulum by the action of the Ca2+-ATPase 
pump, potentially leading to a faster production of force through quicker detachment of the acto-myosin 
bridges. Thus, the effects of Cr supplementation on multiple high intensity short duration bouts (<30 s) could 
be due to reduced fatigue symptoms. In anaerobic endurance exercise lasting from 30-150 seconds, Cr 
supplementation improves both work and power. However, it seems that Cr is more effective in short duration 
exercise bouts rather than longer bouts (Cooper et al. 2012).  
 
2.1.3 Aerobic exercise 
Some studies on predominantly aerobic exercise provide evidence of Cr supplementation 
effectiveness. Endurance activities lasting more than 150 seconds depend mainly on oxidative phosphorylation 
and it seems that there is an inverse relationship between the ergogenic potential of Cr supplementation and 
the increase in exercise duration. Nevertheless, Cr supplementation was suggested to cause a change in 
substrate utilization during aerobic activity possibly leading to an increase in steady state endurance 
performance. However, results are controversial as while some studies demonstrated decreased blood lactate 
accumulation and increased lactate threshold, others found no differences between supplemented and control 
groups. Furthermore, the content of glycogen limits the onset of fatigue and performance in exercise lasting 
more than 1 hour. Cr supplementation might enhance muscle glycogen accumulation and GLUT4 expression 
when combined with glycogen depleting exercise. Cr alone is not able to increase muscle glycogen, but a 
combination of Cr and carbohydrate supplementation leads to higher muscle glycogen stores (Cooper et al. 
2012). 
 
2.1.4 Other Creatine supplementation effects in sport 
Cr supplementation may negatively affect range of motion (ROM). This could be due to increasing 
intracellular water content resulting in greater muscle stiffness and resistance to stretch, or enhanced muscle 
cell volume affecting neural outflow from the muscle spindles. However, active ROM was measured 
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immediately after the loading phase, so the effect of Cr on ROM after several weeks of a maintenance phase 
should also be investigated (Sculthorpe et al. 2010). 
Other effects rather than ergogenic may benefit athletes involved in high intensity intermittent and 
endurance sport. For example, Cr may enhance recovery, reduce the risk of injury, and help individuals 
recover from injuries at a faster rate (Kreider et al. 2017). CM supplementation may also help athletes recover 
from intense training. As previously mentioned, Cr can amplify the increased muscle glycogen loading. 
Glycogen replenishment is important to promote recovery and prevent overtraining during high intensity 
training periods. Thus, CM supplementation might help to maintain optimal glycogen level for athletes who 
are involved in sport where significant glycogen depletion occurs during training and/or performance. 
Evidence also suggests that Cr supplementation may reduce muscle damage and/or enhance recovery from 
intense exercise. For example, Cooke et al. (2009) investigated the effects of Cr supplementation on muscle 
force recovery and muscle damage following intense exercise. The results from this study showed higher 
isokinetic (+10%) and isometric (+21%) knee extension strength during recovery and lower CK level (-84%) 
in the days after high intensity exercise in participants supplemented with Cr. In general, studies have found 
that Cr enhances recovery by reducing inflammatory and muscle damage markers, such as CK, prostaglandin 
E2, and tumor necrosis factor α, and by reducing the increase of lactate dehydrogenase after fatiguing exercise 
or intermittent anaerobic sprint exercise. Therefore, there is a strong evidence that CM supplementation could 
be used to enhance glycogen loading; to experience less inflammation and/or muscle enzyme efflux following 
intense exercise; and to tolerate high volumes of training (Kreider et al. 2017).   
Regarding injury prevention role, CM seems to be safe because reported incidence of musculoskeletal 
injuries, dehydration, muscle cramping, gastrointestinal upset, and renal dysfunction in studies appears only 
anecdotally. On the contrary, researchers have reported that Cr users experienced significantly less incidences 
of muscle cramping, heat illness/dehydration, muscle tightness, muscle strains, and total injuries compared to 
athletes who did not use Cr. Furthermore, due to the effect of Cr on promoting gains in muscle mass and 
improving strength, there has been interest in examining the effects of Cr supplementation on muscle atrophy 
rates as a result of limb immobilization and during rehabilitation (Kreider et al. 2017). For example, Hespel 
and colleagues (2001) investigated the effect of Cr supplementation (20 g/day down to 5 g/day) on atrophy 
rates and rehabilitation outcomes in subjects who had their right leg casted for two weeks. During the 10 weeks 
rehabilitation phase, subjects performed three sessions per week of knee extension rehabilitation. Results from 
this study showed greater enhancement in the cross-sectional area of muscle fiber (+10%) and peak strength 
(+25%) after the rehabilitation period in the supplemented group, suggesting an effect of Cr in hypertrophy. 
Indeed, these changes were associated with an increase of myogenic regulating factor 4 and myogenic protein 
expression. Moreover, another study showed that CM supplementation counteracts the decline in muscle 
GLUT4 protein level that occurs during immobilization and promotes the increase of GLUT4 protein content 
during subsequent rehabilitation training in healthy subjects (Op’t Eijnde et al. 2001). Collectively, these 
findings suggest that Cr supplementation is able to reduce the level of muscle atrophy and detrimental effects 
on muscle associated with immobilization, while also promoting greater gains in strength during rehabilitation.  
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2.2 Creatine supplementation in clinical field 
2.2.1 Neurodegenerative diseases 
Physiopathology of neurodegenerative diseases is related to a loss of distinct neuron population. 
Neuronal loss or dysfunction could lead to several neurological diseases whose phenotype depends on the 
neuronal loss localization and on neurons degeneration velocity. Common processes in neurodegeneration 
are protein aggregation, transcriptional dysregulation, excitotoxicity, oxidative stress, impaired energy 
metabolism, and mitochondrial dysfunction. These processes are involved in disorders such as Huntington’s 
disease (HD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Alzheimer’s disease 
(AD).  
In particular, impaired energy metabolism together with mitochondrial dysfunction are thought to 
play an important role in the pathogenesis and progression of these neurodegenerative diseases as a primary 
and/or secondary mechanism in the neuronal death cascade (Beal 2011). While other mechanisms, namely 
protein aggregation and altered transcription, may amplify the bioenergetics dysfunction, the impaired energy 
metabolism may cause pro-apoptotic signaling, oxidative damage, excitotoxicity, and compromised nuclear 
and mitochondrial DNA repair (Fig 5). Therapeutic strategies that act on mitochondrial dysfunction and on 
impaired energy metabolism may be useful in the treatment of neurological diseases. Therefore, in the last 
few decades, CM supplementation to improve the global cellular bioenergetics and as a neuroprotective agent 
has been investigated in different neurodegenerative disorders (Salomons and Wyss 2007).  
As already mentioned in the first chapter, Cr and its metabolite, PCr, play fundamental role in the cell. 
First, they are important in spatial and temporal buffering of high-energy phosphates leading to improved 
bioenergetics defects, but Cr may also indirectly benefit other pathophysiological mechanisms by improving 
cellular homeostasis. Cr counteracts energy depletion by connecting cellular sites of ATP consumption and 
production. ATP produced by the CK reaction using PCr is the major source of energy in the brain and is 
tightly coupled to Cr and PCr level within the cell. Therefore, CM supplementation may help to prevent 
reduced energy stores and to improve neuronal function through enhancing Cr level. Cr is also involved in 
regulating glycolysis, in stabilizing the mitochondrial, octameric form of CK, and in inhibiting the MPTP, 
whose opening is associated with both apoptotic and necrotic cell death mechanisms. Another potential 
neuroprotective mechanism of Cr supplementation is the ability of PCr to stimulate synaptic glutamate uptake 
and thus to decrease the accumulation of extracellular glutamate and the subsequent excitotoxicity. Cr has also 
been demonstrated to act as a direct antioxidant, scavenging ROS that may further potentiate mitochondrial 
dysfunction (Salomons and Wyss 2007; Sartini et al. 2012). Interestingly, the neuroprotective effects of Cr 
may be independent from mitochondrial CK. Brustovetsky and colleagues showed that Cr had no effect on the 
MPTP in isolated brain mitochondria (Brustovetsky et al. 2001). In addition, Beal and colleagues reported that 
Cr supplementation in mice deficient in uMt-CK increased brain level of Cr and PCr, suggesting that the 
neuroprotective effects of Cr are the result of the maintenance of PCr and ATP level and are not due to the 
inhibition of the MPTP (Klivenyi et al. 2004a). Of great interest is the fact that oral CM supplementation (20 
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g/d over 4 weeks) in healthy human volunteers is able to significantly increase (8.7% overall) the Cr pool in 
the brain (Dechent et al. 1999). 
 
2.2.2 Mitochondrial involvement in neurodegeneration 
Mitochondria are organelles that play a critical role in regulating the energy status of the cell through 
oxidative phosphorylation, yielding ATP; they are important especially in tissues with large ATP 
requirements such as heart, skeletal muscle, and brain. Thus, the primary role of mitochondria is to supply 
and regulate energy for the cell. However, mitochondria are also involved in controlling processes such as 
excitotoxicity and apoptosis that lead to cell death (Fig. 5). Mitochondrion is the principal source of ROS 
production within cells. It has been demonstrated that several toxins that specifically target the electron 
transport chain of mitochondria, namely 3-nitropropionic acid, 1-methyl-4-phenyl-2,3,6-tetrahydropyridine, 
rotenone, and malonate are able to reproduce the phenotype of HD or PD. In fact, the finding that 1-methyl-
4-phenyl-2,3,6-tetrahydropyridine toxicity was related with impairment of complex I function of the electron 
transport chain indicates that mitochondria may be involved in the pathogenesis of PD (Beal 2011). 
The involvement of this organelle in apoptosis is evident by the fact that it contains several 
proapoptotic proteins, which, after being released into the cytosol, result in cell death. These proapoptotic 
proteins include cytochrome c and apoptosis inducing factor, endonuclease G, SMAC/Diablo, and 
OMI/HTRA2, modulated by proteins of the Bcl2/Bax family. In particular, Bcl2 localized in the outer 
mitochondrial membrane prevents the release of proapoptotic factors, while Bax enhances their release. The 
MPTP is crucial in releasing these factors and the following cell death pathways onset. The MPTP might be 
formed and opened by several triggers, such as an increase in calcium concentration, a reduction in membrane 
potential, an increase in inorganic phosphate, a reduction in adenine nucleotides or an elevation of ROS (Beal 
2011).  
Mitochondrial oxidative phosphorylation involves a series of electron transfers within the inner 
mitochondrial membrane. The inefficient transfer of electrons may result in the generation of unstable and 
potentially damaging ROS, leading to mitochondria to be considered as the primary source of ROS within 
the cell. It has been estimated that approximately 2% of all oxygen is converted into ROS. The production of 
mitochondrial ROS is thought to initiate early apoptotic triggering events. In fact, they can directly induce 
cytochrome c dissociation from the inner mitochondrial membrane and cause subsequent release into the 
cytosol. In addition, ROS can directly act to facilitate MPTP opening. Antioxidant enzymes including 
manganese superoxide dismutase, glutathione peroxidase, and phospholipid hydroperoxide glutathione 
peroxidase limit the accumulation of ROS within the matrix. ROS can also indirectly affect the apoptotic 
pathways through activation of mitogen-activated protein kinases (MAPKs) and of several redox sensitive 
transcription factors involved in the expression of anti- and pro-apoptotic gene expression (Beal 2011). 
Oxidative stress is a common feature of most neurodegenerative diseases, and the mitochondria as the 
main source of ROS production is the possible target of therapeutic strategies to address such diseases. In this 
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scenario, CM supplementation and its neuroprotective effects may represent an important tool to prevent or 
treat these neurodegenerative diseases. Cr has been shown to be effective in a variety of animal and cellular 
models of neurodegenerative diseases including AD, PD, ALS, and HD. Such neuroprotective effects involve 
the bioenergetics, antiapoptotic, antiexcitotoxic, antioxidant properties of Cr. However, the strong evidence 
found in animal studies is not properly replicated in human clinical studies including PD, HD, and ALS patients 
(Bender and Klopstock 2016).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3 Alzheimer’s disease 
Alzheimer’s disease (AD) is a common neurodegenerative disorder, which leads to progressive 
dementia. This disease is characterized by the loss of neurons, particularly of the cholinergic system, as well 
 
 
Fig. 5. Mitochondrion-related neuronal dysfunction in neurodegenerative diseases. Mutant protein 
aggregation can disrupt the mitochondrial membrane potential and alter Ca2+ influx induced by 
excitotoxins. Furthermore, respiratory enzyme activities impairment might cause reduction of ATP 
synthesis and increase of ROS level. In addition, ROS generation can cause further damage to cellular 
macromolecules through oxidation, nitrosylation, and peroxidation that may contribute to neuronal 
injury and death. Moreover, the cytochrome c release from the damaged/dysfunctional mitochondria 
onsets the apoptotic cascade and the caspases activation, which result in neurons death. Impaired 
energy metabolism can onset pro-apoptotic signaling, impair cellular homeostasis, and counteract 
nuclear and mitochondrial DNA repair. These pathological mechanisms are further able to exacerbate 
mitochondrial damage and energy loss. Creatine administration may improve intracellular high-energy 
phosphate stores, ameliorating different cellular functions and neurons survival. 
 
Figure adapted from Salomons and Wyss 2007. 
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as deposition of extracellular amyloid plaques and intracellular neurofibrillary tangles (Andres et al. 2008; 
Querfurth and La Ferla 2010). It has been shown that the earliest detectable defects in AD patients are induced 
by impaired energy metabolism and mitochondrial electron transport chain dysfunction, and interestingly 
such defects often precede the amyloid deposition. In addition, there is strong evidence for increased 
oxidative damage to proteins and DNA, as well as to mitochondrial DNA (Bonda et al. 2010). AD brain 
homogenates showed a marked decrease in CK activity, which may be related to oxidative stress (Aksenov 
et al. 2000). This is because the CK enzyme presents highly sensitive cysteine residues that can be easily 
modified by an oxidative insult. Pettegrew et al. (1994) reported that AD patients have reduced level of brain 
PCr at the onset of symptoms, and decreased oxidative metabolism in later stages. In addition, in a transgenic 
model of AD, increased Cr deposits were found (Gallant et al. 2006). The most plausible explanation for this 
Cr deposition is that the oxidative stress associated with AD, resulting in impairment of both cytosolic and 
mitochondrial CK, reduces the generation of PCr from Cr, thereby enhancing the cytosolic Cr level.  
Furthermore, it has been suggested that the amyloid precursor protein directly interacts with and binds 
to mitochondrial CK (Li et al. 2006). Brewer and Wallimann (2000) demonstrated that Cr supplementation 
protects against oxidative mediated conversion of octameric MtCK to the dysfunctional dimeric MtCK. 
Therefore, increased Cr level following supplementation may protect the CK system and delay the inactivation 
of CK induced by ROS, which occurs in AD patients (Aksenov et al. 2000). Another possible mechanism 
underling the neuroprotective effect of Cr is related to the AMPK signaling activated by Cr supplementation 
shown in skeletal muscle cells (Ceddia and Sweeney 2004). The activation of the AMPK pathway is crucial in 
regulating mitochondrial content and function in a PGC-1α dependent pathway (Zong et al. 2002). If Cr may 
improve mitochondrial content and/or function by activating AMPK, this is potentially beneficial. This is 
particularly the case since a reduction in PGC-1α level has been reported in post-mortem brain tissue of AD 
subjects, which correlates with elevating numbers of neurofibrillary tangles, as well as pathologic and clinical 
grade prior to death (Qin et al. 2009). 
 
2.2.4 Parkinson’s disease 
Parkinson’s disease (PD) is characterized by a degeneration of dopaminergic neurons resulting in the 
clinical phenotype of progressive bradykinesia, rigidity, tremor, and gait disorders. Several molecular 
mechanisms contribute to induce dopaminergic neuronal loss and dysfunction in PD. There is substantial 
evidence that mitochondrial dysfunction plays a role in the pathogenesis of this disease (Beal  2009). Studies 
showed that there is a decreased complex I activity of the mitochondrial electron transport chain in the 
substantia nigra of post-mortem tissue of PD patients, and there is also lower complex I activity in platelets 
of patients with early PD. Furthermore, toxins including 1-methyl-4-phenyl-2,3,6-tetrahydropyridine and 
rotenone specifically inhibit complex I of the electron transport chain, leading to a depletion of ATP and 
increasing the importance of the impaired energy metabolism in PD physiopathogenesis (Beal 2011).   
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These toxins cause selective loss of dopaminergic neurons and if chronically administered they result 
in the development of α-synuclein aggregates, a pathologic feature of PD. 1-methyl-4-phenyl-2,3,6-
tetrahydropyridine is converted in 1-methyl-4-phenylpyridinium (MPP+) by monoamine oxidase B. MPP+ 
enters into neurons through the dopamine transporter and subsequently it is accumulated within the 
mitochondria, where it blocks complex I of the electron transport chain and causes increased production of 
ROS. A number of genetic causes of PD are also correlated with mitochondrial dysfunction. These genetic 
causes include nuclear genes that codify for α-synuclein, parkin, DJ-1, PINK1, LRRK2, and Omi (Thomas 
and Beal 2007). It is interesting to note that defects in parkin and PINK1 are involved in a critical pathway, 
which utilizes autophagy to remove damaged mitochondria. The depolarization of mitochondria, which 
occurs with uncoupling agents, causes the expression of PINK1 on the membrane of the mitochondria 
(Narendra et al. 2010). Subsequently PINK1 is recognized by parkin, which ubiquinates the mitochondrion 
leading to autophagy of the damaged mitochondria. Thus, because of the important role of mitochondrial 
impairment and oxidative damage in the pathogenesis of PD, Cr supplementation has been hypothesized as 
a neuroprotective treatment.  
Several studies using Cr supplementation as a neuroprotective agent in PD have been conducted both 
in animals as well as in humans. The first study showed Cr to be strongly neuroprotective in a toxic mouse 
model for PD, targeting mitochondrial function (Matthews et al. 1999). 1% Cr supplementation for 2 weeks 
before 1-methyl-4-phenyl-2,3,6-tetrahydropyridine injection was able to abolish its deleterious effects on 
dopaminergic neurons. A second study reported additive neuroprotective effects, when Cr was combined with 
the cyclooxygenase 2 (COX-2) inhibitor rofecoxib (Klivenyi et al. 2003). However, it is important to note that, 
in 2004, rofecoxib has been withdrawn from the market after controversial results about safety, because it has 
been showed to increase the risk of cardiovascular events (Juni et al. 2004). Subsequently, the combination of 
Cr with coenzyme Q10 was found to be more neuroprotective, leading to less lipid peroxidation damage and 
less α-synuclein accumulation within dopaminergic substantia nigra neurons in mice (Yang et al. 2009). 
Following these encouraging results in animal models, human investigations began.  
The first randomized placebo-controlled clinical trial of oral Cr supplementation (up to 4 g/day) over 
2 years in 60 PD patients was negative for primary outcomes. However, positive results were found in measures 
for mood and behavior, and Cr-treated patients increased their dopamine dosage to a lesser degree in 
comparison to control group over the 2 years (Bender et al. 2006). At the same time, a futility randomized 
placebo-controlled clinical trial using 10 g of Cr per day for 12 months and involving 200 early PD patients 
showed that Cr could not be rejected as futile with regard to slowing clinical disease progression (NINDS 
NET-PD Investigators 2006). A meta-analysis of the 194 patients of the two pilot or Phase II trials reported no 
effect on either motor function or activities of daily living, however determined that data were insufficient to 
draw a firm conclusion (Xiao et al. 2014). In 2007, a multicenter Phase III double-blind neuroprotection 
randomized placebo-controlled clinical trial was conducted by the National Institute of Neurological Disorders 
and Stroke (NINDS). A total of 1741 patients with early and stable PD were recruited, and received either 10 
g of Cr per day or placebo (Kieburtz et al. 2015). This study that should have lasted 5 years was terminated for 
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futility, because no differences in any of the five individual outcome measures (activities of daily living, 
ambulatory capacity, disease-specific health problems, cognitive functioning, and overall outcome) nor in the 
aggregate measure were observed. There were also no differences in secondary outcome measures (levodopa 
equivalent daily dose, depression, cognition, or quality of life). A recent clinical trial investigating Cr 
supplementation combined with coenzyme Q10 in 75 PD patients for 18 months revealed that the cognitive 
decline determined by the Montreal Cognitive Assessment (MoCA) was reduced in the treated group compared 
to the placebo group. However, there was no significant treatment effect on motor symptoms, as quantified by 
the Unified Parkinson's Disease Rating Scale (Li et al. 2015). 
 
2.2.5 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease caused by degeneration of motor 
neurons in the spinal cord and of corticospinal neurons in the motor cortex (Hervias et al. 2006), leading to 
muscle weakness, atrophy, and spasticity. In some cases, genetic abnormalities causing ALS were found, for 
example mutations in copper zinc superoxide dismutase, a cytosolic enzyme responsible for scavenging and 
reducing ROS in the cell (Peters et al. 2015). With this knowledge, a transgenic mouse model was developed 
with the G93A mutation in SOD, characterized by progressive loss of motor neurons, and increasing 
weakness. A fraction of SOD1 is localized on the outer mitochondrial membrane, where it may interfere with 
the function of Bcl2, a neuroprotective antiapoptotic protein, and VDAC (Beal 2011). Some of the 
pathological mechanisms in ALS include mitochondrial dysfunction, glutamate-mediated excitotoxicity, and 
oxidative stress, which are potential targets for Cr-mediated neuroprotection.  
Oral Cr supplementation induced dose-dependent improvement of motor performance, and extended 
survival in the G93A mice (Klivenyi et al. 1999). Furthermore, Cr administration reduced the loss of neurons 
in both the substantia nigra and the motor cortex, and limited the oxidative damage. Other studies using Cr 
supplementation combined with other potentially neuroprotective agents in the same animal model showed 
a comparable but not additive neuroprotective effect of Cr compared to the standard clinical ALS drug, 
riluzole (Snow et al. 2003). In contrast, the combination of minocycline and Cr as well as the combination 
of Cr with the COX-2 inhibitors celecoxib and/or rofecoxib, produced additive neuroprotective effects 
(Zhang et al. 2003; Klivenyi et al. 2004b).  
Due to this neuroprotective evidence, Cr supplementation (with doses of 5 or 10 g/day) was 
investigated in three human randomized placebo-controlled trials. However, these trials did not show any 
beneficial effect of Cr on survival and/or disease progression in patients with ALS (Shefner et al. 2004; 
Groeneveld et al. 2003; Rosenfeld et al. 2008). This was confirmed by a systematic Cochrane collaboration 
meta-analysis covering these three individual randomized placebo-controlled trials (Pastula et al. 2012). One 
phase II randomized placebo-controlled trial (http://www.clinicaltrials.gov, NCT01257581) using 30 g of Cr 
or one of two different tamoxifen doses was completed, however results are not published yet. Results from 
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humans studied are disappointing, suggesting that the SOD transgenic mouse may not be predictive of 
therapeutic outcome in patients with sporadic ALS.  
 
2.2.5 Huntington’s disease 
Huntington’s disease (HD) also known as Huntington’s chorea because of an abnormal ‘‘dancelike’’ 
body movements (called chorea), is an inherited autosomal dominant progressive neurologic disorder. This 
disease is characterized by impaired coordination, as well as cognition and psychiatric abnormalities. The 
cause of HD is identified in trinucleotide repeat (CAG) in the huntingtin gene, resulting in an expansion of a 
polyglutamine stretch in the huntingtin protein. The huntingtin protein is ubiquitously expressed in both the 
nervous system and peripheral tissues. Possible mechanisms with which mutant huntingtin is thought to 
induce toxic effects to neural tissue are transcription dysregulation, proapoptotic signaling, oxidative injury, 
excitotoxicity, inflammation, malfunctioning proteolysis, metabolic dysfunction, and mitochondrial 
dysfunction (Beal 2011). 
Cr administration was studied both in toxic (3-nitropropionic acid or malonate, inhibitors of the 
respiratory chain complex II) as well as in genetic HD animal models. In toxic models, oral Cr produced lower 
lesion volume and higher brain ATP and PCr level (Matthews et al. 1998). The transgenic mouse models of 
HD are considered more suitable models to study human disease. In these models, Cr administered prior to the 
development of the phenotype showed significant neuroprotection, improvement in motor performance, and 
higher overall survival (Ferrante et al. 2000; Andreassen et al. 2001a). More relevant to application in human 
HD is that the same effect was obtained when Cr was used after symptom onset (Dedeoglu et al. 2003). So far, 
two phase II randomized placebo-controlled trials of Cr in human manifest and one in premanifest HD have 
been published. The first study using 5 g/day of Cr for 1 year had no effect on clinical outcome measures in 
41 HD patients (Verbessem et al. 2003). A higher dose of 8 g of Cr per day was given to 64 HD patients for 4 
months. Cr seemed to cross the BBB, and was well tolerated (Hersch et al. 2006). While there was no effect 
on clinical outcomes, Cr was able to reduce elevated serum level of 8-hydroxy-2’-deoxyguanosine (8OH2’dG), 
a marker of oxidative stress. The following PRECREST trial recruited 64 patients in a premanifest state or at 
50% genetic risk of HD, and involved supplementation of either up to 30 g of Cr per day or placebo, with a 
double-blind protocol for 6 months (Rosas et al. 2014). Diarrhea and nausea occurred more often under this 
high-dose Cr regime supplementation, but Cr was well tolerated and proved to be safe. Cr slowed the rate of 
region specific brain atrophy in repeated MRI scans, but did not show any effect on secondary clinical outcome 
measures. The Cr Safety, Tolerability, and Efficacy in HD (CRESTE) phase III trial then set out to recruit 650 
early symptomatic HD patients to receive up to 40 g of Cr per day for up to 4 years. However, the study was 
terminated for futility after recruiting 553 participants, because there were no positive Cr effects in slowing 
functional loss in HD patients, even at this very high Cr doses. Side effects, mainly gastrointestinal, were 
significantly more frequent in participants using Cr. Serious adverse events, including deaths, were more 
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common in the placebo group. However, it is interesting to note that subgroup analysis suggested that men and 
women might respond differently to Cr supplementation (Hersch et al. 2017).  
 
2.2.7 Creatine supplementation in neurodegenerative diseases conclusions 
In conclusion, prominent results from animal studies on neurodegenerative disease are not properly 
translated to human studies. This is especially true for Cr administrated in AD, PD, and ALS patients, while 
some positive results were found in human studies using HD patients. Common speculative reasons for failed 
neuroprotection trials are that Cr was administrated too late in the course of the disease or at low dosage, that 
trials are not long enough, or that the wrong outcome measures were chosen. In the case of Cr in PD, animal 
models might be not suitable to draw firm conclusions for human PD. In these animal models, Cr was usually 
administered before the application of toxins, suggesting the use of a different animal model in the future. 
Furthermore, it could be interesting to understand if there is a gender response to Cr supplementation in PD 
patients, given that rodent models of depression suggest a therapeutic Cr gender effect, favoring female 
animals (Allen et al. 2012). In addition, the comparison between vegetarian and non-vegetarian patients in 
the PD phase III trial would be an interesting subgroup analysis. It was suggested that healthy vegetarian 
women had improved memory functions compared to omnivores upon supplementation of 20 g of Cr for 5 
days (Benton and Donohoe 2011). However, Cr seems to not provide neuroprotection in PD (Bender and 
Klopstock 2016). Furthermore, an interesting study by Lowe et al. (2015) showed a different distribution of 
CTs in the human brain. The CT is hardly identified in the striatum and the dopaminergic substantia nigra 
neurons, the cell population that predominantly dies in human PD. Thus, it might be that Cr supplementation 
effects depend on brain area and cell type. However, data showed no difference in CT distribution between 
rodents and humans (Mak et al. 2009). This does not explain the discrepancy between the promising 
preclinical data and the overall disappointing results of randomized controlled human trials.  
Also in the case of ALS, Cr seems not to be neuroprotective in human studies. The reasons for this 
could be low dosage or the late timing of Cr administration in the course of the disease. Regarding the Cr 
dosage, 10 g of Cr per day used in human trials represent still only 10% of the dose used in rodent models 
(Bender et al. 2006). In the typical mouse studies, brain Cr increased by 21 ± 3.8%, while in the human 
randomized trials, increases between only 7.5 and 13% could be obtained (Ferrante et al. 2000; Atassi et al. 
2010; Hersch et al. 2006; Lyoo et al. 2003). In the case of timing of Cr administration, neuroprotective Cr 
effects were demonstrated in rodent models, where Cr supplementation commenced weeks prior to injection 
of the neurotoxin (Matthews et al. 1998, 1998; Yang et al. 2009). This study design seems not to be suitable 
for human studies, where patients show an established disease, as this may be too late for Cr to exert 
significant neuroprotective effects. This is why the recent work by Rosas and colleagues (2014) is so 
noteworthy, because they found a way to administer Cr to premanifest HD patients. Indeed, they reported 
significantly decreased brain atrophy rates in the Cr group (30 g day for 6 months) compared to the placebo 
group. If this were to translate into clinical patient benefit in the long-term (III phase study), it would be 
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important for other neurodegenerative diseases, such as PD or ALS, to have recognized early biomarkers or 
genetic testing for high disease risk or early disease activity, so that Cr supplementation could begin as early 
as possible. However, in genetic HD animal models, Cr was still neuroprotective, even when administrated 
after the onset of disease-related symptoms (Dedeoglu et al. 2003). At least in animals, it seems not a 
prerequisite for Cr to be given prior to the onset of the pathophysiological processes. Finally, Cr does not 
easily cross the BBB, thus, it could be useful to study other chemical forms of Cr rather than CM, such as 
cyclocreatine or PCr-magnesium-complex-acetate, or other administration strategy like intrathecal 
administration. This latter solution is far from practical in the context of neurodegenerative disease though, 
but would possibly be an alternative in states of critical acute brain energy failure, such as in global cerebral 
ischemia or traumatic brain injury.  
In summary, Cr has failed as a neuroprotective treatment in neurodegenerative diseases with the 
exception that it may be beneficial in premanifest HD patients when given at high doses, which will have to 
be further examined in a phase III trial. Furthermore, Cr could be considered a neuroprotective prophylactic 
strategy in conditions with imminent neurological damage. In fact, Cr was recently shown to prevent 
neuropsychological deficits in healthy volunteers under experimental oxygen deprivation (Turner et al. 2015).  
 
2.3 Inborn errors of metabolism 
2.3.1 Mitochondrial encephalomyopathies and hyperammonemia 
Mitochondrial encephalomyopathies are a heterogeneous group of diseases characterized by a broad 
range of biochemical and genetic mitochondrial defects, as well as variable types of inheritance. 
Mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes (MELASs) syndrome are 
the most common maternally inherited mitochondrial disorders (Andrea et al 2008). While the exact cause 
of specific neuronal death is unknown, mechanisms associated with neuronal energetic deficiency and 
subsequent lactic acidosis, and NMDA receptor-mediated excitotoxicity, have been implicated. Therapeutic 
strategies have been adopted as the result of single case studies, and they are based on the use of antioxidants, 
respiratory chain substrates, and cofactors such as Cr and coenzyme Q10 (Salomons and Wyss 2007). 
In the few clinical trials using MELAS patients, Cr administration showed a normalization of seizures 
and an improved vocabulary. Notably, Cr supplementation resulted in a reversal of the paracrystalline 
intramitochondrial inclusions in the muscle, which were shown to consist mainly of crystallized uMt-CK. In 
Leigh syndrome (LS) patients suffer from characteristic focal necrotizing lesions in one or more regions of 
the CNS, including the brainstem, thalamus, basal ganglia, cerebellum, and spinal cord. The clinical 
symptoms of this disorder depend on which areas of the CNS are involved. The most common underlying 
cause for LS is a defect in oxidative phosphorylation. In a recent case report, oral Cr supplementation was 
shown to improve behavioral and physiological functions of a child suffering from LS (Komura et al. 2003). 
Rodriguez and co-workers (2007) reported that a combination therapy (CM, coenzyme Q10, and lipoic acid) 
favorably influenced surrogate markers of cellular energy dysfunction in an inhomogeneous population of 
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patients with mitochondrial cytopathies. The outcome of this randomized, double-blind, placebo-controlled, 
crossover study design suggests that targeting the final common pathway of mitochondrial dysfunction 
positively influences the course of the diseases.  
Another inborn error that could benefit from Cr supplementation is the one regarding ammonia 
metabolism. Inborn errors of ammonia metabolism, such as urea cycle deficiencies and organic acidemias, can 
lead to Cr depletion in developing brain cells, likely through interference with Cr transport and synthesis 
pathways. Interestingly, it has been shown in vitro that treating developing brain cells exposed to ammonium 
with Cr protects them from axonal growth inhibition due to ammonium exposure, which may be one of the 
irreversible effects of hyperammonemia on CNS development (Braissant et al. 2002). Cr administration to 
hyperammonemic neonates and children may therefore represent a method to protect the developing CNS from 
some of the deleterious effects of ammonium (Andres et al. 2008). 
 
2.3.2 Cerebral creatine deficiency syndromes 
In the last two decades, a new group of inborn errors that affect the biosynthesis and the transport of 
Cr, namely the cerebral creatine deficiency syndromes (CCDSs) has been discovered. These CCDSs include 
two autosomal recessive disorders that affect Cr biosynthesis, the arginine:glycine amidinotransferase 
(AGAT) deficiency and guanidinoacetate methyltransferase (GAMT) deficiency, and an X-linked defect that 
affects the creatine transporter (CT deficiency). These disorders are characterized by cerebral Cr deficiency 
as detected in vivo by 1H magnetic resonance spectroscopy (MRS) of the brain, and specific abnormalities 
in metabolites of Cr metabolism in plasma and urine. Specifically, in urine and plasma, abnormal 
guanidinoacetic acid (GAA) level is found in AGAT deficiency (reduced GAA) and in GAMT deficiency 
(increased GAA), while CT deficiency is characterized by an elevated Cr/creatinine ratio in the urine of 
males. Mental retardation, expressive speech and language delay, autistic like behavior and epilepsy are 
common features of CCDSs, however in GAMT deficiency, the neurotoxicity of elevated GAA level leads 
to a more severe phenotype. Cr biosynthesis deficit treated with Cr may show a partial remission of the 
symptomatology, or a total prevention in case of early diagnosis or presymptomatic treatment. On the 
contrary, an effective treatment for CT deficiency it is not still available. The discovery of these inborn 
diseases is important for understanding the physiological functions and pharmacological potential of Cr 
(Salomons and Wyss 2007). 
 In two Italian sisters affected by AGAT deficiency, CM supplementation was able to induce almost 
the complete normalization of cerebral Cr level, as well as an improvement in psychomental development 
(Bianchi et al. 2000). In their younger brother, the disease was diagnosed prenatally and Cr supplementation 
was started at the age of 4 months, due to the inefficiency of breast-feeding in enhancing Cr level in the child. 
Growth and psychomotor development were normal compared to his sisters (Battini et al. 2006). This 
suggests that early neurological sequelae might be preventable by early treatment.  
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In GAMT deficiency, oral CM supplementation was able to increase cerebral Cr up to 90% in a 24 
months-old German boy, followed by improvements in extra-pyramidal movement disorder and head 
nodding. However, other symptoms such mental retardation, speech development and autism-like behavior 
were not ameliorated by Cr supplementation. One reason for the incomplete clinical improvement seems to 
be the accumulation of GAA, which is still compromised following Cr supplementation. A possible solution 
to the accumulation of GAA could be represented by Cr supplementation combined with dietary restriction 
of arginine and low doses of ornithine or combined with high ornithine dosage. Arginine is the immediate 
precursor of GAA, namely the substrate of AGAT reaction, while ornithine is the competitive inhibitor of 
AGAT. Thus, increasing level of Cr together with reducing GAA accumulation improves clinical symptoms 
in such patients. This was true especially for autistic-like behavior, movement disorder, and some cognitive 
ability, while speech delay and general cognitive development remained poor or only slightly improved. The 
experience with the only patient diagnosed at birth and treated at a pre-symptomatic stage of the syndrome 
suggests that early treatment might widely prevent neurological manifestations (Salomons and Wyss 2007). 
Finally, in CT deficiency syndrome, in contrast to GAMT and AGAT deficiency, GAA level was 
normal and oral Cr supplementation was not effective in restoring cerebral Cr level (Cecil et al. 2001). The 
main biochemical hallmark of CT deficiency syndrome is an increased urinary Cr/creatinine ratio in males 
(Stöckler-Ipsiroglu and Salomons, 2006). In addition to affected males who have a hemizygous mutation in 
CT, 80 females having a heterozygous mutation (carriers) have also been identified. However, diagnosis is 
more complicated in females, and clinical symptoms involve learning disabilities and therapy-resistant 
epilepsy. The cause of CT deficiency is still unknown, but it is interesting to note that GAA is a competitive 
inhibitor of CT. Therefore, due to the absence of a functional CT, GAA absorption could be compromised. 
This might interfere with GAA methylation and, therefore, with the Cr biosynthesis. Currently, despite there 
is not an effective therapy, supplementation with high doses of arginine and glycine, which are the primary 
substrates for Cr biosynthesis, combined with high doses of CM is being investigated. In addition, alternative 
strategies that facilitate Cr transport into the brain either by modified transport via carrier molecules (e.g., 
peptides) or by supplementation with suitable Cr analogs might be developed (Salomons and Wyss 2007). 
Diagnostic work-up in CCDS patients is generally commenced only when symptoms are manifested. 
If these symptoms are due to an irreversible brain impairment, the reason why Cr supplementation is generally 
not efficacious is evident. On the other hand, when treatment can be initiated prior to the occurrence of 
irreversible damage, clinical symptoms may be entirely and permanently prevented. In fact, the diagnosis of 
CCDSs could precociously occur, in prenatal or neonatal periods, through 1H-MRS that reveals the cerebral 
Cr deficit or through measures of urinary GAA concentration or urinary Cr/creatinine ratio (Salomons and 
Wyss 2007). 
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2.4 Creatine supplementation: safety and side effects 
There is a growing interest about Cr supplementation both in healthy and clinical populations. 
However, to develop a therapeutic agent it is important to assess its safety. Although Cr seems to be well 
tolerated by most participants in short-term studies, some anecdotal reports and case-reports suggest that Cr 
supplementation may lead to various side effects, such as muscle cramping, gastrointestinal discomfort and 
renal dysfunction. It is important to say that when a drug, food or supplement is considered safe this does not 
mean the product is harmless, but that the benefits outweigh the risk of side effects in that population. Thus, 
Cr would be clinically useful if the positive effects, including increased muscle strength and reduced fatigue, 
outweighed the possible side effects, such as muscle cramping.  
In the last few decades, several studies examining Cr safety were conducted especially in animals. 
However, data from animal models may not be directly applicable to the effects of Cr in humans. Additionally, 
the appearance of side effects seems to be species-specific as shown by Tarnopolsky et al. (2003) in a study 
that compares mice and rats. In this study, CM supplementation had caused hepatitis in mice (0.025 and 0.05 
g·kg-1·day-1), but not in rats (2% weight/weight). To date, Cr appears to be safe because randomized control 
studies have not found clinically significant deviations from normal values in renal, hepatic, cardiac or muscle 
function. However, a number of side effects were anecdotally reported in some case reports, including muscle 
cramping, muscle damage and rhabdomyolysis, dehydration, renal dysfunction, and gastrointestinal, hepatic 
and cardiovascular problems, raising some doubts about Cr supplementation safety.  
 
2.4.1 Muscle dysfunction 
Muscle dysfunction following Cr supplementation reported by popular media comprises cramps, 
muscle damage and rhabdomyolysis. Increased muscle Cr stores subsequent to Cr supplementation is 
associated with increments in total body water (Powers et al. 2003) and enhanced compartment pressure 
(Hile et al. 2006). This leads to speculation that Cr supplementation could cause muscle dysfunction. 
However, the effect of Cr supplementation on mild and severe markers of skeletal muscle dysfunction have 
been studied in cross-sectional studies, clinical trials, and case studies, showing no increase in dysfunction 
after supplementation. Although some researchers reported muscle cramping in Cr users (common 
loading/maintenance Cr dosage), no control groups were used in these studies, indicating that the relationship 
between Cr and muscle cramps cannot be determined from these experiments (Greenwood et al. 2000; Juhn 
et al. 1999). A more recent study showed that Cr supplementation (21.6 g/day of CM for 7 days) does not 
affect plasma sodium and potassium, or dehydration level following exercise, and thus it does not increase 
muscle cramping (Watson et al. 2006).  
Collectively, clinical studies of the interactions between Cr supplementation and fatiguing exercise 
indicate that Cr supplementation does not amplify muscle damage. In particular, Cr supplementation does 
not decrease strength and ROM, and does not increase muscle soreness, serum CK or lactate dehydrogenase 
activity (Rawson et al. 2001, 2007). On the contrary, Cr administration might protect muscle from damage 
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during certain types of stressful exercise (Santos et al. 2004). It is important to note that serious adverse 
events associated with severe muscle damage, for example rhabdomyolysis, which may occur infrequently 
(1 in 10,000 exposures), are difficult to detect in the small clinical trials typically conducted on Cr 
supplementation involving less than 50 participants. Few cases of rhabdomyolysis in Cr users have been 
reported in the literature. However, these are singular cases, that might be due to higher and prolonged 
supplementation dosage (25 g/d for 5 years) (Robinson 2000), to a combination with other supplements (e.g. 
ephedrine, natural diuretics) (Kuklo et al. 2000; Sandhu et al. 2002) or to Cr supplemented after knee surgery 
(Sheth et al. 2006). Thus, it is unclear what role the Cr supplementation plays in inducing rhabdomyolysis. 
Cr is often incorrectly correlated with dehydration. In fact, Cr supplementation (25 g/d of Cr for 7 days 
and 5 g/d for the remaining 21 days) is able to enhance total body water (Powers et al. 2003) and is more 
correctly considered as a hyper-hydrating agent. It has been suggested that Cr supplementation may increase 
intracellular water, reducing available water for heat loss through sweat evaporation. However, Powers et al. 
(2003) demonstrated that Cr supplementation did not affect fluid distribution. In addition, other studies 
demonstrated that hyper-hydration induced by Cr administration does not impair thermoregulatory or 
metabolic responses to prolonged exercise in the heat. In fact, Cr may attenuate thermoregulatory responses 
and prevent heat-related injuries and performance decrements (Kilduff et al. 2004).  
 
2.4.2 Renal Dysfunction 
Cr and its major metabolite, creatinine, are excreted by the kidney. Creatinine is used as an important 
clinical marker for renal function. In particular, creatinine clearance is an indicator of glomerular filtration 
rate. Generally, creatinine clearance in studies is calculated from a single serum creatinine sample and the 
subsequent use of the Cockcroft-Gault equation. However, the use of serum creatinine as a marker for renal 
function requires several assumptions. To use serum creatinine as a marker for renal function, the daily 
anabolic production of Cr should be constant as well as the conversion of Cr to creatinine. However, during 
Cr supplementation, the first requirement is violated because the supraphysiologic doses consumed far 
exceed daily endogenous synthesis, while the second condition is preserved, although serum creatinine tends 
to rise due to increased Cr stores (Salomons and Wyss 2007).  
Clinical studies investigating changes in serum creatinine following Cr supplementation have found 
serum creatinine either does not change or increases, but remains in the normal range. The possible increment 
of serum creatinine raises some concern because it is assumed this increase might indicate reduced kidney 
function. However, studies that investigate both serum and urine creatinine to estimate renal function in healthy 
individuals and patients have found no effect of Cr supplementation on kidney function (Salomons and Wyss 
2007). As of yet, only three case studies have reported subjects with renal dysfunction during CM 
supplementation (Koshy et al. 1999; Pritchard and Kalra 1998; Revai et al. 2003). However, in all of these 
studies the patients either had previous renal disease (i.e., glomerulosclerosis with relapsing nephrotic 
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syndrome) or had ingested 4 to 100 times the recommended daily dose of Cr for prolonged periods of time 
with or without other anabolic agents (Salomons and Wyss 2007). 2007). 
 
2.4.3 Other possible side effects 
Other problems anecdotally related to Cr supplementation are gastrointestinal distress and diarrhea. 
However, studies using recommended dosages of Cr have not reported such complaints. There is one case 
study related to Cr ingestion and cardiac dysfunction, in which a 30 year-old vegetarian male developed 
diarrhea and cramps after one month of Cr supplementation, and subsequently changed to a different Cr 
supplement and developed palpitations and dyspnea (Kammer 2005). It is unknown what role Cr played in 
this case.  
Some doubts about the safety of Cr supplementation linked to the related production of metabolites. 
Cr can be converted to formaldehyde and hydrogen peroxide through a minor metabolic pathway. 
Formaldehyde has the potential to cross-link proteins and DNA leading to cytotoxicity. Thus, there is some 
concern about possible cytotoxicity following Cr supplementation, particularly after a study conducted by 
Yu and Deng (2000) found an increase in urine formaldehyde after Cr supplementation. However, markers 
of protein or DNA cross-linking, or measures of oxidative stress, were not investigated. Poortmans et al. 
(2005), examining urinary methylamine, formaldehyde and formate following 21 g/d for 14 days Cr 
administration, found increments in both methylamine and formaldehyde. This increase was below the upper-
limit of normal (Salomons and Wyss 2007). 
The data collected so far suggest that there are few adverse effects associated with Cr 
supplementation when administrated at recommended doses. Muscle dysfunction, impaired thermoregulation 
or dehydration, gastrointestinal- and renal-related side effects are anecdotally reported with Cr 
supplementation, but data do not support this. Furthermore, information regarding the safety of Cr 
supplementation is available from relatively small clinical studies lasting short periods, and examining 
healthy volunteers. There is a lack of evidence from studies involving patients, larger numbers of subjects, 
long periods of time, and doses above recommendations. Finally, it is important to include placebo controls 
in future studies to assess the possible increased risk of side effects caused by Cr supplementation.   
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Chapter 3 
 
CREATINE SUPPLEMENTATION DURING PREGNANCY 
 
 
Creatine supplementation during pregnancy will be discussed in this chapter. The pleiotropic effect of 
creatine could represent an important and economic tool in order to prevent and treat hypoxic-ischemic events 
that might occur pre-, peri-, and post-natally. In the context of maternal creatine supplementation, it is relevant 
to understand that the embryonic CNS is more reliant on maternal creatine supply. Therefore, before addressing 
the creatine supplementation during pregnancy, the differences between adult and developing CNS regarding 
Cr synthesis and transport will be described.  
 
3.1 Creatine and the Central Nervous System 
To better understand how Cr supplementation could be important and effective during pregnancy, it 
is necessary to explain the differences between the adult and the embryonic CNS in relation to the different 
expression of the Cr transporter (CT1) and the Cr biosynthesis enzymes (AGAT and GAMT). Cr synthesis 
occurs mainly in the kidneys, pancreas and liver, however, the brain is known to also express the Cr 
transporter and biosynthesis enzyme during development and adulthood. The expression of AGAT, GAMT 
and CT1 in different brain cells varies during CNS development. For this reason, the capacities to take up Cr 
from the periphery and endogenous synthesis are different between the embryonic and the adult CNS. In 
particular, the embryonic CNS is more dependent on Cr provisions from periphery, likely from maternal 
origin, than endogenous synthesis, while the adult CNS depends more on endogenous Cr synthesis because 
of the limited permeability of the BBB (Braissant et al. 2001). The importance of Cr for CNS function and 
development was made evident by the discovery of the cerebral Cr deficiency syndromes. In fact, as already 
mentioned in the second chapter, in these inborn diseases, in which the expression of AGAT, GAMT or CT1 
is absent, the main clinical symptoms are related to CNS impairment. Patients with AGAT and GAMT 
deficiency can be treated with high doses of Cr supplementation, with a partial restoration of the brain Cr 
pool being reached within months, while Cr supplementation in CT1 deficiency patients is ineffective 
(Salomons and Wyss 2007). 
In the CNS, the Cr/PCr/CK system plays critical functions in maintaining high energy levels essential 
for CNS development and function, achieved through ATP re-synthesis and buffering (Braissant 2012). In 
particular, studies demonstrated that Cr is important in the migration of growth cones, in dendritic and axonal 
growth, Na+/K+-ATPase activity, neurotransmitters release, membrane potential maintenance, Ca2+ 
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homeostasis and ions gradients restoration (Salomons and Wyss 2007). Other studies have also demonstrated 
that Cr acts as a neuromodulator and neurotransmitter and, finally, that it is one of the main cellular osmolytes 
(Hanna-El-Daher and Braissant 2016). 
In mammals, half of Cr is acquired from the diet and half is synthesized in the periphery through the 
dissociated expression of the first enzyme AGAT in the kidney, where GAA is released for the second 
enzyme GAMT expressed in the liver. While it had long been thought that brain Cr was of peripheral origin, 
AGAT and GAMT are well expressed in the CNS, suggesting that the brain is able to produce its own Cr. 
Furthermore, the expression of CT1 occurs only in microcapillary endothelial cells at BBB, but not in 
astrocytes. This is especially the case in their feet lining the BBB, suggesting a limited permeability for 
peripheral Cr through the BBB, and that the brain could be more dependent on endogenous synthesis of Cr 
(Braissant 2012). However, despite the restricted efficiency of CNS Cr uptake from the periphery, 
demonstrated in vivo both in rodents (Perasso et al. 2003) as well as in patients with AGAT and GAMT 
deficiency supplemented with Cr (Schulze 2005), Cr (and GAA) can cross barriers (Tachikawa and Hosoya 
2011). However, it is well known that this transfer of peripheral Cr into the brain is limited. Oral Cr 
supplementation in healthy human volunteers with approximately 60 times the daily Cr requirement leads to 
a very modest 5% to 10% enhancement in their total cerebral Cr (Cr+PCr) after one month of 
supplementation (Dechent et al. 1999). 
The brain is separated from the blood through different barriers, which firmly regulate exchanges 
between the periphery and CNS. The two most important barriers are the BBB and the blood-cerebrospinal 
fluid barrier (BCSFB). In particular, the BBB, the largest barrier between the periphery and the brain (Fig. 
6A), consists of non-fenestrated microcapillary endothelial cells (MCEC) linked together through tight and 
adherent junctions that preclude paracellular diffusion of molecules between the blood and CNS. The tight 
regulation of exchanges through the BBB is allowed by specific transporters on luminal and abluminal sides 
of MCEC and through a very limited pinocytosis. Furthermore, other structures limit and strongly regulate 
these exchanges, such as cells adjacent to the abluminal side of MCEC (namely pericytes which cover 
approximately 32% of the microcapillary surface; and astrocytic feet which cover more than 98% of the surface 
made by MCEC and pericytes) and a specific extracellular matrix which sheathes MCEC, pericytes and 
astrocytic feet and restricts molecular diffusion between MCEC and CNS. BCSFB (Fig. 6B) is located in the 
lateral, third and fourth ventricles and is characterized by unique apical tight junctions between the choroid 
plexus epithelial cells (CPEC), which are responsible for the secretion of cerebrospinal fluid and also express 
specific transporters allowing regulated exchanges between the cerebrospinal fluid and blood (Braissant 2012). 
In physiological conditions, the adult CNS is able to synthesize Cr and has a limited supply from the periphery; 
however, in the embryonic CNS there is a different situation depending on the different expression of CT1 and 
Cr biosynthesis enzymes. This difference between adult and embryonic CNS might clarify the importance and 
effectiveness of Cr supplementation during pregnancy.   
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3.1.1 AGAT, GAMT and CT1 expression in the adult Central Nervous System 
The adult mammalian CNS is able to synthesize Cr and has a limited supply of Cr from the periphery 
due to the expression of AGAT and GAMT in brain, as well as the limited expression of CT1 along the barriers. 
Specifically, AGAT is expressed in all the principal CNS structures, with notably high levels in the 
telencephalon and cerebellum (Braissant et al. 2005). This enzyme is expressed in all the main cell types of 
the brain, namely neurons, astrocytes and oligodendrocytes. In the barriers, AGAT is expressed by 
microcapillary endothelial cells (MCEC) and the astrocytes contacting them (at the BBB), as well as by the 
choroid plexus and ependymal epithelia (Braissant et al. 2001). GAMT is also expressed among the principal 
structures of the adult mammalian brain, in particular in the telencephalon (mainly in the corpus callosum and 
hippocampus), pons nuclei and cerebellum. Furthermore, GAMT is expressed in neurons, oligodendrocytes 
and astrocytes, and while it is not expressed in MCEC, it is present in the astrocytes that contact them (at the 
BBB), as well as in the choroid plexus and ependymal epithelia (Braissant et al. 2001; Tachikawa et al. 2004). 
Recently, it was found that AGAT and GAMT, in most areas of the rat brain, seem to be expressed in a 
dissociated manner, being rarely co-expressed within the same cell (Braissant et al. 2010). This dissociated 
AGAT and GAMT expression suggests the transfer of GAA from AGAT- to GAMT-expressing cells through 
CT1 to complete Cr synthetic pathway (Braissant 2012; Hanna-El-Daher and Braissant 2016). Because CT1 
appears to be essential for Cr biosynthesis, the low cerebral Cr level found in CT1 deficiency patients despite 
normal AGAT and GAMT in CNS might be explained. In vivo, mouse and rat CNSs can obtain Cr from the 
circulation against the concentration gradient, but this uptake of Cr through the BBB seems almost inefficient. 
 
Fig. 6. (A) Transport of creatine at the blood-brain barrier. Cr is taken up by the CNS from the periphery through CT1 
(SLC6A8 in the figure) expressed on MCEC at the BBB, but in limited amounts due to the absence of CT1 in the 
surrounding astrocytes, as well as the difficult diffusion of Cr through the ECM surrounding the BBB. Therefore, the brain 
needs its own synthetic pathway to ensure sufficient levels of Cr, and does so by expressing AGAT and GAMT. (B) 
Transport of creatine at the blood-cerebrospinal fluid barrier (BCSFB). CPEC are able to take up Cr both from the blood 
and CSF. Arg: arginine; AGAT: arginine:glycine amidinotransferase; Cr: creatine; ECM: extracellular matrix; GAA: 
guanidinoacetate; GAMT: guanidinoacetate methyltransferase; Gly: glycine; MCEC: microcapillary endothelial cells 
(BBB); P: pericyte; SLC6A8: Cr transporter (CT1); CPEC: choroid plexus epithelial cells (BCSFB); CSF: cerebrospinal 
fluid; Ep: ependymal epithelium. 
 
Figure adapted from Braissant 2012 
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CT1 is present in the main regions of the adult mammalian brain. In rats and mice, CT1 is found in neurons 
and oligodendrocytes, and is expressed by MCEC but not by astrocytes sheathing them (except for a very few 
in the cerebellum (Mak et al. 2009)), in contrast to the expression of AGAT and GAMT. CT1 is also found in 
the choroid plexus and ependymal epithelia. Thus, in the mature CNS, Cr can only cross the BBB only through 
the limited space occupied by MCEC, while it cannot cross the BCSFB (Braissant 2012).  
Two strikingly coherent patterns of AGAT, GAMT, and CT1 expression are found in different brain 
structures. In the first pattern, present in most brain areas, high amount of cells do not express either AGAT, 
GAMT or CT1 (20-50%), the proportion of cells that express CT1 only (Cr “users”) remains below 15%, while 
AGAT and GAMT are not co-expressed. In these structures, separation of AGAT and GAMT expression might 
facilitate the fine tuning of GAA and Cr synthesis, in particular for the two main roles of Cr in cellular energy 
and neuromodulation/neurotransmission, while the efficient uptake of Cr and GAA by brain cells might be 
essential to maintain their extracellular concentrations in low ranges, thereby allowing 
neuromodulation/neurotransmission by Cr while avoiding the toxic effects of GAA (Braissant et al. 2010; van 
de Kamp et al. 2013). It is noteworthy that the dissociated expression of AGAT and GAMT in the CNS (at the 
intercellular level) appears organized as in the periphery, where it may also support tight regulation of Cr 
synthesis. In the second pattern, specific brain areas such as the hippocampus, cerebellar Purkinje neurons or 
hypothalamic nuclei present large amounts of cells that co-express AGAT + GAMT (40-60%), and large 
amounts of cells that express CT1 (45-65%). This suggests that these neuronal layers permanently require high 
Cr levels, in line with their high CK activity (Hanna-El-Daher and Braissant, 2016). 
Interestingly, the observed presence of GAMT and CT1 mRNAs in neuronal processes (axons and 
dendrites) suggests that GAMT and CT1 transcripts might be transferred along axons and dendrites in order to 
allow CNS cells to translate these proteins at their required locations. This would permit the cell to react 
quickly to instantaneous peripheral demands of, or the re-uptake of, Cr. This process is crucial 1) in CNS 
development during synaptogenesis or growth cone migration which has been demonstrated to be connected 
directly with CK (mammals) or arginine kinase (insects) activity, and 2) in adulthood for the described function 
of Cr as a central neuromodulator (Salomons and Wyss 2007).   
 
3.1.2 AGAT, GAMT and CT1 expression in the developing Central Nervous System 
During embryogenesis, the fetal requirements for Cr are partially supported by Cr actively transported 
from the mother to the fetus (Ireland et al. 2008). However, AGAT, GAMT and CT1 are also well expressed 
during vertebrate embryogenesis, including in the CNS (Braissant et al. 2005; Wang et al. 2007; Ireland et al. 
2009). Nevertheless, the low levels of AGAT, GAMT and CT1 (GAMT in particular) during the initial 
developmental stages suggests that in contrast with the adult brain, the fetal CNS predominantly depends on 
external Cr sources, either from the fetal periphery or of maternal origin. This can be correlated with CT1 
expression in the whole fetal brain at early stages, with particularly high levels in the periventricular area and 
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choroid plexus, the principal metabolic exchange areas of the developing CNS before microcapillary 
angiogenesis and differentiation of the BBB occur (Braissant et al. 2005; Braissant 2012). 
Recently, studies about AGAT, GAMT and CT1 gene expression in the developing embryonic 
mammalian CNS have allowed understanding of the difference between the embryonic and adult CNS 
regarding Cr transport and biosynthesis. AGAT and CT1 are widely expressed in rat brains at embryonic day 
12.5 (E12.5), while GAMT appears later, and only in scarce regions of the developing brain: at E15.5 GAMT 
is identified only in striatum and pons, and only at E18.5 it is found that in the neocortex, striatum, 
hippocampus, pallidum and spinal cord. An interesting expression pattern was shown in the two structures 
responsible for exchanges between the periphery and the CNS, the choroid plexus and MCEC that build the 
BBB. CT1 is highly expressed in the choroid plexus (E15.5 and E18.5), but is absent from MCEC (E18.5), a 
situation reversal in comparison to adulthood (Braissant et al. 2001). AGAT is not present in the choroid plexus 
but is found in MCEC at E18.5, while GAMT is not present in both structures throughout the entirety of 
embryonic development (Salomons and Wyss 2007). 
Furthermore, it is important to underline the different roles of BCSFB and BBB between the embryonic 
and adult CNS. The BCSFB develops earlier in comparison to the BBB, and is therefore the first structure 
responsible for exchanges between the periphery and CNS during development (Fig. 7). Cr uptake by the CNS 
from the periphery is likely made possible by the much higher levels of CT1 expression in the CPEC (BCSFB) 
during development than in the mature brain, as well as by the very high expression of CT1 in fetal ependymal 
cells and the periventricular zone, as shown in rats (Braissant et al. 2005) (Fig. 7). In contrast, CT1 is not 
detectable at the BBB in the first stages of MCEC development (Braissant et al. 2005), while it is expressed in 
mature MCEC (Braissant et al. 2001; Ohtsuki et al. 2002) (Fig. 7).  
The better ability of the developing CNS to obtain Cr from the periphery is evident in pre-symptomatic 
treatments of AGAT and GAMT deficiencies that seems to entirely prevent the phenotype of these syndromes. 
The discovery of these diseases suggests that Cr plays a critical role in the development of CNS higher 
cognitive functions, such as speech acquisition, during the first months and years after birth, and that Cr 
supplementation before irreversible damage occurs might prevent clinical symptoms of AGAT and GAMT 
deficiencies permanently. As described above, early Cr supplementation in postnatal stages and during the first 
years after birth may also promote Cr entry into the brain, at stages when the BBB is not as firmly regulated 
as in more mature stages, and when CT1 expression on the BBB and BCSFB may still largely promote entry 
of peripheral Cr into the brain (Braissant et al. 2005; Ireland et al. 2009), in contrast to adulthood (Braissant et 
al. 2001) (Fig. 7).  
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In conclusion, AGAT, GAMT and CT1 are extensively present in the brain, both during development 
and in adulthood. Most probably because of the absence of CT1 on the astrocytic feet that sheath 
microcapillaries, the adult CNS shows a limited capacity to obtain Cr from the periphery, as has been 
demonstrated in vivo both for mice and humans. Thus, the adult CNS seems to depend more upon endogenous 
Cr synthesis than on Cr uptake from the circulation. Differently, GAMT is expressed only at the end of the 
fetal CNS development, while CT1 is present on the first exchange structures between the CNS and periphery, 
namely the ependymal epithelia and choroid plexus. Thus, the embryonic CNS might be more dependent on 
Cr supply from the periphery than on endogenous synthesis, at least in the first stages of development. 
Therefore, even if human studies have demonstrated a limited increase of cerebral Cr following 
supplementation, it could be hypothesized that Cr administration during pregnancy results in a higher efficacy 
and a higher transfer of Cr to the brain.   
 
 
Fig. 7. Transport of creatine at blood-cerebrospinal fluid barrier (BCSFB) and blood-brain barrier (BBB) in the 
developmental versus the adult brain. Fetal and perinatal CNS may predominantly depend on Cr supply from the 
periphery. This is probably made possible during development by the high expression of CT in CPEC at BCSFB 
as well as in fetal ependymal cells and periventricular zone. In contrast, Cr is supplied to the mature brain by its 
limited uptake from the periphery, predominantly at BBB, as well as by endogenous synthesis. AGAT: 
arginine:glycine amidinotransferase; CNS: central nervous system; Cr: creatine; CSF: cerebrospinal fluid; GAMT: 
guanidinoacetate methyltransferase; MCEC: microcapillary endothelial cells (BBB); CT: Cr transporter. 
 
Figure adapted from Braissant 2012 
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3.2 The need for a treatment that decreases the probability of perinatal morbidity and mortality 
Premature birth and neonatal hypoxic-ischemic encephalopathy (HIE) are the main areas in obstetric 
and neonatal medicine characterized by the lack of an effective prophylactic treatment. Morbidity and mortality 
are known to be higher for neonates born pre-term. Indeed, infants that survive to the premature birth may 
experience severe, life-long CNS disabilities such as cerebral palsy, occurring not only as a consequence of 
prematurity, but also from co-existing obstetric problems, namely intrauterine infections, chronic fetal 
hypoxia, or the difficulties that arise during resuscitation of the newborn (Dickinson et al. 2014a). 
Maternal corticosteroid supplementation for impending preterm birth has been established to 
significantly decrease the risk of neonatal decease, respiratory distress, cerebroventricular hemorrhage, and 
necrotizing enterocolitis, and to limit the necessity for neonatal respiratory support and intensive care (Roberts 
et al. 2006). Prenatal magnesium sulfate supplementation has also been demonstrated to decrease the risk of 
cerebral palsy if provided to women immediately before the preterm birth (Doyle et al. 2009). Trials using 
xanthine oxidase inhibitor allopurinol supplementation during pregnancy as a tool for protecting the fetal brain 
from oxidative stress induced by hypoxia were conducted (Kaandorp et al. 2012). However, these therapies 
are provided relatively late, and only when it is obvious that preterm labor will occur, or when the fetus is 
already clearly under severe hypoxia.  
Most perinatal deceases occur in the Third World environment. The World Health Organization 
estimates that approximately 9 million newborns experienced hypoxia during birth each year, and it is 
estimated that 1.2 million of these cases culminates in death (29% of global neonatal deaths), with similar 
numbers of newborns developing severe disability. In addition to cerebral palsy, cognitive and behavioral 
dysfunctions and psychiatric diseases including autism and schizophrenia occur often in infants born from 
pregnancies characterized by obstetric complications such as prematurity, fetal growth restriction, or birth 
hypoxia. In developing an effective prophylactic treatment for preterm birth and birth-related HIE, the greatest 
challenge is related to the difficulty of predicting their occurrence (Dickinson et al. 2014a). Thereby, strategies 
that prevent rather than rescue perinatal brain damage are necessary. 
Head cooling or total body cooling are the most encouraging and generally used clinical treatments for 
HIE, however the need for immediate application following the onset of HIE is one of several limitations. In 
fact, if applied in the 6 hours immediately after birth, hypothermia can reduce mortality, and significantly 
limits the incidence of neurodevelopmental disabilities. A multi-center review established that no additional 
side effects are related to the use of hypothermia treatment, although adverse outcomes have been reported 
when hypothermia was applied to healthy term infants (Gluckman et al. 2004). Thus, the prolonged period 
prior to assessing the neonate as being “suitable for treatment” reduces the efficiency of this intervention. In 
this scenario, it is important to find a treatment that could be safe for both mother and fetus, which could also 
be administrated before hypoxia-ischemia occurrence. 
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3.2.1 Creatine as a therapy for the third trimester 
Cr is not yet used in human pregnancy, but positive results from animal experiments have shown that 
maternal Cr supplementation protects the fetal CNS, diaphragm, and kidneys against hypoxic damage at term 
(Cannata et al. 2010; Ellery et al. 2013; Ireland et al. 2011). This suggests that Cr administered in the second 
or third trimester of human pregnancy could provide protection to all pregnant women against the risk of 
prenatally or perinatally acquired brain damage, similar to the manner in which folate is nowadays utilized to 
prevent defects of the neural tube during pregnancy. Cr supplementation is also different from treatments such 
as hypothermia and magnesium sulphate by providing protection to numerous organs against the physiological 
challenge during the transition from fetal to newborn life. Cr and its pleiotropic effects are hypothesized to 
benefit several fetal tissues where vasoconstriction, oxidative stress, or glutamate toxicity might occur, in 
addition to the main role of preserving mitochondrial function and ATP buffering (Dickinson et al. 2014a). 
Pregnancy is a condition characterized by high metabolic demands with extra nutritional requirements by the 
mother, and even in healthy pregnancy, there are increased levels of oxygen and nitrogen free radicals, a key 
source of which is the placenta (Myatt et al. 2004). Fetal tissues, particularly the developing CNS, are 
vulnerable to oxidative stress especially if infection or inflammatory processes are present. Thus, an 
antioxidant agent may be useful to protect the fetus against oxidative stress, especially in late pregnancy.  
Another reason for considering the use of Cr supplementation during pregnancy relates to the 
possibility that preterm newborns might experience Cr depletion because endogenous synthesis is not yet fully 
developed. It seems that the fetus is dependent on Cr supply from the mother. In humans, and probably in most 
omnivore species, Cr may cross the placenta through active transport; in fact, it seems to first accumulate in 
the placenta before subsequently diffusing down a concentration gradient into fetal circulation (Davis et al. 
1978; Koszalka et al. 1972; Miller et al. 1977). However, it is unclear when the capacity for Cr synthesis 
develops in the fetus. Studies using early spiny mice demonstrate that the reno-hepatic axis of Cr synthesis 
develops late in gestation (Ireland et al. 2009), and if this occurs also in human pregnancy it would indicate 
that infants born prematurely have an under-developed capacity for Cr synthesis, and potentially representing 
an increased risk of becoming Cr deficient. As already mentioned in the second chapter, the fact that the fetus 
depends on maternal Cr supply is suggested by the knowledge that newborns diagnosed with cerebral Cr 
deficiency develop signs of neurological dysfunction in the days or weeks following birth, suggesting that Cr 
deficiency was not present before birth, even if the ability to synthesize Cr on their own during pregnancy was 
absent. It is also important to investigate the capacity for reabsorption of Cr from glomerular filtrate in 
neonates, because preterm birth is often associated with renal dysfunction. Urine composition, such as urinary 
lactate/creatinine ratio, has been measured to assess the risk of developing HIE in neonates, however the ability 
of the kidney to retain Cr in preterm newborns has not yet been investigated (Dickinson et al. 2014a). 
The occurrence of birth before the major organs are sufficiently developed to meet the postnatal life 
demands is a crucial problem. Therefore, the Cr status of premature neonates needs close attention. In human 
premature births, the heart, lungs, kidneys, and brain are immature. In these cases, respiratory and 
cardiovascular support is often required, and resuscitation procedures usually provide further risk of hypoxic-
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ischemic injury to the brain. It is clear that acute hypoxic event leads to depletion of ATP and PCr in human 
infants and children, confirming animal studies and confirming that Cr supplementation should be studied as 
a treatment to prevent and treat hypoxic-ischemic SNC damage at birth (Dickinson et al. 2014a).  
 
3.2.2 Creatine as a clinically important and safe treatment 
Higher intracellular Cr/PCr stores following CM supplementation or subcutaneous injections have 
been shown to be neuroprotective in numerous animal models of neurodegenerative diseases and acute CNS 
damage. Furthermore, Cr supplementation has recently been shown to improve cognitive function in normal 
and elderly people (Benton et al 2011; Rawson and Venezia 2011), and cognitive and motor skills in sleep-
deprived subjects (Cook et al. 2011).  
The relevant statutory authorities in the EU (European Medicines Agency), UK (Medicine & 
Healthcare Products Regulatory Agency), USA (Federal Drug Administration) and Australia (Therapeutic 
Goods Administration) have yet to classify Cr, CM and creatine phosphate, and they have also not been 
assigned to a category for administration in pregnancy. While long-term Cr supplementation in adult humans 
seems to be safe, some concerns could arise before recommending use in human pregnancy, as detailed studies 
have yet to be conducted. In a human study, Bohnhorst et al. (2004) demonstrated that although 14 days of 
oral Cr supplementation was ineffective to treat apnea in premature infants, it was well tolerated by the 
premature neonates with no side effects noted. So far, no evidence has found effects upon body weight or body 
composition modifications in mothers and fetuses after Cr supplementation. Nevertheless, given that 
pregnancy is usually linked with fluid balance changes in women, some concerns could arise, as Cr is an 
osmolyte, and in very high concentrations may be linked to enhanced cellular water uptake, aggravating fluid 
shifts during pregnancy (Dickinson et al. 2014a).  
Understanding the neuroprotective effects of Cr to treat and prevent brain damage in the adult is 
important in order to appreciate how it might be supplemented to prevent or attenuate fetal and neonatal CNS 
injury. Indeed, many adult neuropathologies in which Cr has been demonstrated to be beneficial also include 
the primary mechanisms of damage induced by hypoxia-ischemia in the immature CNS, namely mitochondrial 
dysfunction, impaired energy metabolism, excitotoxicity and oxidative stress. However, it is important to 
consider that Cr supplementation may represent a multi-organ protective agent for the fetus and neonate in 
contrast to the other current therapies, namely magnesium sulphate or head cooling.  
The “pleiotropic” effects of Cr go beyond the spatial-temporal buffering of ATP, and are summarized 
as follows:  
1) Acid-base balance role: the rephosphorylation of ADP utilizes a proton (H+), reducing the intracellular 
acidity during hypoxic events (Walliman et al. 2011). Besides this, Cr has the ability to scavenge free 
radicals (Lawler et al. 2002; Sestili et al. 2006). Therefore, the Cr/PCr system has the capability to 
modulate variations of intracellular acid-base balance that can arise during events of acute hypoxia in 
a direct antioxidative manner. 
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2) Antioxidant actions: perhaps associated with this effect on H+ accumulation, Cr has been shown to 
have an antioxidant effect (Lawler et al. 2002; Sestili et al. 2006). Furthermore, Ireland and colleagues 
(2011) showed that maternal Cr supplementation from mid-pregnancy prevented the increase of 
malondialdehyde (product of lipid peroxidation) levels caused by intrapartum hypoxia in spiny mouse 
pup brains. 
3) Post-ischemic recovery of protein synthesis: Cr pre-treatment in the oxygen-glucose deprived adult rat 
(Carter et al. 1995) and fetal guinea pig hippocampal slices (Berger et al. 2004) provides a faster 
recovery of the decreased protein synthesis that occurs before neuronal cell loss in the post-ischemic 
brain, resulting in a more positive histological outcome.  
4) Improved cerebral vascular function: Cr pre-treatment provides quicker recovery of cerebral blood 
flow during reperfusion following middle cerebral artery occlusion, probably due to larger dilator 
responses to extra-luminal K+ and acidosis (Prass et al. 2007). 
5) Interaction with the benzodiazepine receptor: Cr may bind to the GABAA receptor, which was 
demonstrated in chick brains (Koga et al. 2005). Furthermore, animals supplemented with Cr showed 
increased GABAergic activity in some brain areas (Pena-Altamira et al. 2005). The anti-excitatory 
effect of the enhanced GABAA receptor activity is probably protective for the developing CNS. 
6) Promoting the uptake of glutamate: The re-uptake of glutamate occurs in an ATP-dependent manner 
by synaptic vesicles, and Cr therefore acts to maintain the ATP required. Furthermore, PCr has been 
demonstrated to promote the uptake of glutamate in synaptic vesicles, and might account for the 
neuroprotective function of Cr against glutamate toxicity in neuronal cell culture (Brewer et al. 2000). 
7) Stabilization of lipid membranes: PCr might interact with phospholipid membranes to stabilize them 
and prevent their permeabilization (Tokarska-Schlattner et al. 2012).  
 
3.3 Protective functions of Creatine against Hypoxic-Ischemic events at birth 
Circa 4 per 1000 live term born have experience of hypoxia-ischemia at birth, and depending on its 
severity and duration, 4-8% of these infants will die. Newborns that survive are typically subject to several 
health problems, caused by irreversible damage to organs such as the brain, kidneys, heart and lungs. The brain 
is the main organ affected by hypoxia-ischemia, with large percentage of survivors suffering brain damage 
followed by lifelong effects including mental and physical disability, cerebral palsy and seizures. However, 
other systemic complications of hypoxia-ischemia, namely acute kidney, muscle, and heart dysfunctions 
should be recognized and treated for overall homeostasis and thus survival (Dickinson et al. 2014a). Studies 
in the early spiny mouse demonstrated that 5% Cr supplementation commenced from half-way through 
pregnancy resulted in a 10-30% increase in Cr levels in fetal tissues (including heart, kidney, liver, brain and 
muscle) and a 2-fold enhancement in the placenta at term (Ireland et al. 2008). The increased amount of Cr in 
the fetal liver at term might act as an additional Cr store available for the newborn that could be, for the reasons 
mentioned above, at risk of Cr depletion. 
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It is important to consider that Cr supplementation does not impair protein expression of the enzymes 
AGAT and GAMT in the neonatal kidneys and liver, which are required for postnatal Cr synthesis (Dickinson 
et al. 2013). Furthermore, Cr administration during normal pregnancy seems to not have side effects on the 
mother or newborn in terms of health status or body composition (Ellery et al. 2016). However, no data are 
available regarding the effects of Cr during pregnancy where fetal growth restriction is present. Animal studies 
using spiny mice have demonstrated protective effects of Cr administration on brain structures (Ireland et al. 
2011), postnatal behavior (Ireland et al. 2008), the diaphragm (Cannata et al. 2010), and kidney structure and 
function (Ellery et al. 2013) following asphyxial birth, suggesting that Cr may also protect preterm infants in 
their premature passage from fetal to neonatal life. 
Cr and PCr are critical in maintaining intracellular ATP and therefore allow cells to extend 
mitochondrial function and counteract the initial metabolic collapse due to hypoxia-ischemia. Cr might also 
act against several secondary responses to hypoxia-ischemia, for example through reduction of oxidative stress 
and promotion of the post-ischemic recovery of protein synthesis. However, it should be note that acting in the 
first phase of hypoxia-ischemia may already prevent secondary responses to the hypoxic event.  
A limitation found in adult studies investigating the neuroprotective effects of Cr is the slow transfer 
of exogenous Cr into the brain, influenced by limited BBB permeability and by CT working close to saturation, 
and leading to the awareness that long-term, high doses of Cr are required to significantly increase Cr levels 
in the brain. Indeed, early studies in mice (Zhu et al. 2004) and humans (Dechent et al. 1999) demonstrated 
that pre-treatment with Cr required several weeks or months before effectively increasing cerebral Cr content 
and acting as a neuroprotective agent against cerebral ischemia (Zhu et al. 2004). However, other studies 
demonstrated effective supplement protocols of shorter duration (one or two weeks), which successfully 
enhanced the amount of Cr in the human brain (Pan et al. 2007; Braissant et al. 2005). Nevertheless, Cr seems 
to reach the immature brain with greater ease through the higher expression of CT1 in endothelial cells of the 
choroid plexus, allowing the developing CNS to acquire peripheral Cr more so than the mature brain.  
In the postnatal rat brain, a subcutaneous injection of Cr at day 10, but not at day 20 produced a 
significant enhancement of the PCr/NTP (nucleoside triphosphate) ratio, and this was able to increase the 
recovery of the cerebral PCr/NTP ratio within 2 h following hypoxia (Holtzman et al 1998). Furthermore, Cr 
administered before hypoxic insult reduced brain edema and the incidence of severe cystic cerebral infarction 
after hypoxic-ischemia in 7 days old rats (Berger et al. 2004). Therefore, it must be considered that Cr 
supplemented to women even for only several weeks in late pregnancy is likely to enhance the resistance of 
the fetal CNS to oxygen deprivation or acidemic/hypercapnia during the birth, or if poor ventilatory efforts by 
the newborn require resuscitative procedures immediately after birth (Dickinson et al. 2014a).  
 
3.4 Which obstetric population could benefit from Creatine supplementation? 
The potential benefit of Cr supplementation during pregnancy may be crucial for several situations 
during pregnancy that lead to preterm birth, and therefore to high risk of HIE, such as preeclampsia and 
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gestational diabetes mellitus. Preeclampsia is a common syndrome of pregnancy that occurs after 20 weeks of 
gestation, characterized by new-onset hypertension together with maternal end-organ dysfunction and/or 
intrauterine fetal growth restriction, and represents a disease associated with nearly 50% of preterm births. 
With an incidence of around 5% of all pregnancies, preeclampsia shows significantly elevated oxidative stress 
levels within the maternal-fetal unit. Gestational diabetes mellitus is another common human pregnancy 
disorder affecting around 7% of women, and is characterized by enhanced oxidative stress and higher risk of 
preterm birth. These pregnancy conditions along with many others, namely cervical incompetence, preterm 
premature rupture of the membranes (PPROM), partial placental abruption and placenta praevia, and fetal 
growth restriction, might benefit from Cr supplementation. These conditions can lead to fetal hypoxia, 
hypoglycemia and activation of the fetal hypothalamic-adrenal axis, causing not only fetal growth restriction 
and preterm delivery but also, potentially, fetal death or stillbirth. Fetus intrauterine death will always involve 
mitochondrial energy impairments. To reduce perinatal morbidity and mortality, therapeutic interventions such 
as bed rest, low dose aspirin, or conventional nutrient supplementation are used with limited success 
(Dickinson et al. 2014a). Cr supplementation could be used as a conservative treatment and it would not 
interfere with other clinical practices. However, while a trial of Cr administration for neuroprotection of the 
human fetus at term has been conducted (Dickinson et al. 2014b), no other clinical trials of Cr supplementation 
in human pregnancy exist. Uterine smooth muscle contains very low Cr levels, and ATP and PCr are quickly 
consumed by uterine activity. Given that uterine activity in late gestation may be uncoordinated and labors 
sometimes “fail to progress”, Cr supplementation during pregnancy might also decrease the caesarean section 
rate (Dickinson et al. 2014a). 
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Chapter 4 
 
EXPERIMENTAL STUDY 
 
 
4.1 Aim of the study 
The brain utilizes large quantities of ATP to preserve normal function, involving the maintenance of 
electrical membrane potentials, ions gradients, Ca2+ homeostasis, and signaling activities (Braissant et al. 
2010). In this scenario, Cr/PCr/CK system plays an important role during rapid changes in ATP demands that 
occur due to physiological activities of neurons, in particular functionally coupling sites where ATP is 
generated (mitochondria and glycolysis) and where it is consumed (ATPases). Furthermore, following the 
discovery of cerebral Cr deficiency syndromes, Cr is well known to play a critical role in CNS development, 
as Cr administration to these pre-symptomatic patients prevents neurological symptoms, such as 
developmental and speech delay, epileptic seizures, autism and severe mental retardation (Braissant et al. 
2011).  
In addition to an ergogenic role, other effects, including antiapoptotic, antioxidant (Sestili et al. 2006), 
and neuroprotective effects (Beal 2011; Sartini et al. 2012) might be important for proper CNS function and 
development (Wallimann et al. 2011; Sestili et al. 2016). A study has shown a neuroprotective role of Cr 
through the improvement of reperfusion rather than a changing of the bioenergetics status in a mouse model 
of stroke (Prass et al. 2007). Furthermore, in in vivo and in vitro rodent models of ischemia/anoxia, Cr perfusion 
before ischemia/anoxia occurrence reduced the volume of damaged brain tissue, and led to neurological 
improvement (Hanna-El-Daher and Braissant 2016). Cr was also proposed as a neuroprotective treatment for 
several neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s disease, as well as 
Amyotrophic lateral sclerosis (Lensman et al. 2006; Beal 2011; Cunha et al. 2014) characterized by 
mitochondrial impairments and oxidative stress. However, the first therapeutic Cr supplementation trials 
appeared rather disappointing, probably due to the limited BBB permeability for Cr, which suggests a need to 
find new means to facilitate Cr uptake by the CNS. Finally, the Cr/PCr/CK system plays an essential role 
during brain development by providing enough ATP for growing axons and dendrites at their growth cone 
extremities, and Cr was found to have pro-differentiation/trophic actions on maturing neuroblasts, suggesting 
an importance also in CNS development (Sartini et al. 2012).  
Due to the pleiotropic effects of Cr upon correct brain function, development, and protection, there is 
growing interest surrounding the possible use of Cr supplementation during human pregnancy. The reason is 
that Cr may represent an important and economic tool in order to prevent and treat CNS damage in case of 
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pre-, peri-, and post-natal hypoxic-ischemic events caused by premature birth or placental insufficiency 
(Dickinson et al. 2014a; Ellery et al. 2016). Maternal Cr supplementation could be important and effective in 
enhancing cerebral Cr of the fetus, because during fetal life, the brain is largely dependent upon the external 
source of Cr, which is likely of maternal origin (Braissant et al. 2007; Ireland et al. 2009).  
Little is known on the effects and safety of Cr supplementation on neuron differentiation, and our in 
vitro study has shown a positive effect of Cr in protecting developing neuroblasts from oxidative stress (Sartini 
et al. 2012), a status closely associated to peri-natal hypoxia-ischemia, which is a severe condition for the 
developing CNS. However, Cr supplementation induced a significant and dose-dependent anticipation of Na+ 
and K+ current expression, and a higher excitability, expressed as number of spikes following depolarization, 
suggesting that Cr administration may affect neuron excitability (Sartini et al. 2012), leaving the safety of Cr 
supplementation during CNS development as an open question. Moreover, in our in vivo study, maternal Cr 
supplementation at low dosage (1% of Cr in drinking water) was demonstrated to affect the morpho-functional 
development of hippocampal neurons in neonatal rats at postnatal day 14-21 (P14-21), showing enhanced 
dendritic tree development, higher intrinsic excitability, larger evoked-synaptic responses and increased Long 
Term Potentiation (LTP) maintenance (Sartini et al. 2016). Since these results were observed at P14-21, thus 
weeks after maternal Cr supplementation (administration ceased one day before delivery), we hypothesized 
the possibility that the faster morphological and functional maturation observed in the hippocampus of the 
pups may be the results of long-lasting modifications in neuronal development triggered during fetal life. 
Because of this evidence, the long-term effects of maternal Cr supplementation on developing (P14-21) and 
adult brains (P60-70), using electrophysiological, morphological, and calcium imaging approaches have been 
investigated in this study. Moreover, considering that LTP is one of the crucial cellular mechanisms involved 
in learning processes, the ability of spatial learning using the Morris Water Maze has been also studied. 
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4.2 Materials and Methods 
4.2.1 Animals and supplementation protocol 
Sprague-Dawley albino rats (Charles River, Italy) were used in this study. The handling and care of 
animals were carried out in conformity with the National Institute of Health Guide for the Care and Use of 
Laboratory Animals. All the experimental procedures were approved by animal subjects review board of the 
University of Urbino and were designed to minimize the number of animals used and their suffering.  
Virgin male and female rats (weighing 200-250 g) were housed in pairs with free access to food and 
water and maintained at an ambient temperature of 22 ± 1 °C with a 12-h light and 12-h dark cycle (lights on 
at 6 a.m. and off at 6 p.m.). After mating, female rats were randomly divided in two groups: 1. Control group 
(CTRL; n=4) drinking tap water; 2. Supplemented group (TREAT; n=4) drinking tap water in which creatine 
(Fluka, Sigma-Aldrich, Italy) was dissolved (1 g/100 ml; Ipsiroglu et al. 2001) from the eleventh day of 
pregnancy to the day before delivery. This Cr supplementation period was decided because of the expression 
of Cr membrane transporters occur at E12.5 in the embryonic CNS (Braissant et al. 2005). Daily weight of rats 
from CTRL and TREAT groups was monitored during the experimental period. In order to verify the effect of 
the hyperexcitability found in the previous study (Sartini et al. 2016) upon the risk of the induction of 
epileptiform activity, the CTRL and TREAT offspring were killed from postnatal day 14 to 21 (P14-21); to 
address the effects of maternal Cr supplementation upon the hippocampus of adult progeny, the CTRL and 
TREAT offspring were killed at P60-70. 
 
4.2.2 Electrophysiological experiments 
Male pups from different CTRL and TREAT litters, aged from P14 to P21 and adult male rats from 
different CTRL and TREAT litters, aged from P60 to P70, were used to obtain hippocampus slices for 
performing electrophysiological recordings in the CA1 subfield. Animals (CTRL, n = 19; TREAT n = 18) 
were killed by decapitation after being anesthetized with intraperitoneal injection of ketamine anesthetization 
(65 mg/kg body weight). The brain was quickly removed and incubated in chilled oxygenated solution 
containing in millimolar: 110 choline Cl_, 2.5 KCl, 1.3 NaH2PO4, 25 NaHCO3, 0.5 CaCl2, 7 MgCl2, 20 
dextrose, 1.3 Na+ ascorbate, 0.6 Na+ pyruvate, 5.5 kinurenic acid (pH = 7.4; 320 mosM). Afterwards, the brain 
was divided into two hemispheres, each of which was prepared for cutting. Hippocampal transversal slices 
(400 µm thick) were obtained from each hemisphere by vibrating microtome (Campden Instruments, USA) 
and allowed to recover at least 1 hour in an interface recovery apparatus with artificial cerebrospinal fluid 
(ACSF) containing in millimolar: 125 NaCl, 2.5 KCl, 1.3 NaH2PO4, 25 NaHCO3, 2 CaCl2, 1.3 MgCl2, 1.3 Na+ 
ascorbate, 0.6 Na+ pyruvate, 10 dextrose, equilibrated with a 95% O2-5% CO2 gas mixture (pH = 7.4; 
320 mosM), before electrophysiological recordings. Each slice was then transferred into a recording chamber 
where it was continuously superfused throughout electrophysiological recordings with oxygenated ACSF at a 
rate of 3 ml/min (Ambrogini et al. 2004; Betti et al. 2011). Here, following an equilibration period, field 
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potential and whole-cell patch-clamp recordings were carried out. Electrophysiological traces were offline 
analyzed using a WinWCP software (Strathclyde Electrophysiology Software, John Dempster, University of 
Strathclyde, UK). 
 
4.2.2.1 Field potential recordings 
In order to investigate the role of maternal Cr supplementation in the generation of epileptiform activity 
in the hippocampus of the progeny, we used one of the most extensively studied models of epilepsy, providing 
blocking synaptic inhibition. Thus, to induce spontaneous epileptiform-like discharges, the hippocampal slices 
obtained from rats at P14-21 of both groups were perfused with ACSF, containing bicuculline methiodide 
(BMI, 50 µM; Sigma), a GABAA receptor antagonist, and 4-Aminopyridine (50 μM, Sigma), a K+ channel 
blocker, in the recording bath. Bipolar stimulating, connected with A385 stimulus isolator (World Precision 
Instruments, USA), and recording electrodes, filled with ACSF, were placed respectively in the Schaffer 
collaterals and in the CA1 cell body layer of the hippocampus. Field potential recordings were carried out 
under visual guidance using a Zeiss Axioskop microscope (Carl Zeiss International, Italy) equipped with an 
infrared video camera connected to a monitor. The parameters analyzed to verify the epileptic threshold were 
the latency of the first interictal event and the frequency of interictal events. 
The effect of maternal Cr supplementation on adult synaptic plasticity was investigated by evaluating 
the ability to elicit LTP in the Schaffer collaterals-CA1 pathway. Recording and bipolar stimulating electrodes 
were prepared, filled with ACSF, and placed in the stratum radiatum of CA1 at approximately 300 µm of 
distance between them. Slices showing extracellular field excitatory postsynaptic potentials (fEPSPs) of at 
least 1 mV in amplitude were used to perform the field potential recordings. Before LTP induction protocol 
application, input-output relationship between fiber volley amplitude and fEPSP slope was constructed 
increasing Schaffer Collateral stimulation intensity applying to the slice square pulses of current (500 μs in 
duration, from 0 to 140 µA, steps of 20 µA) with A385 stimulus isolator (World Precision Instruments, USA). 
Then, test pulses at 30-s of intervals were applied to elicit baseline responses; afterward, Schaffer collaterals 
were stimulated using 3 stimulus patterns every 5 seconds, each one characterized by 10 trains of 100 Hz 
applied for 0.1 s separated by an interval of 1.2 s; the fEPSP was then monitored by recordings for 40 min. 
fEPSP slope (between 10% and 80% of the max) was analyzed and taken as measures of synaptic strength; 
values were normalized to the mean value obtained over the last 15 min of the baseline period and expressed 
as a percentage of this baseline value (Betti et al. 2011). 
 
4.2.2.2 Patch-clamp recordings 
To investigate the effects of maternal Cr supplementation on the electrophysiological properties of 
CA1 pyramidal cells, patch-clamp recordings in whole-cell configuration were carried out under visual 
guidance using a Zeiss Axioskop microscope (Carl Zeiss International, Italy) equipped with an infrared 
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videocamera connected to a monitor. Recording pipettes were pulled from borosilicate glass capillaries (World 
Precision Instruments, USA) using a vertical puller (model PP-830 Narishige, Japan) and had 3-5 MΩ tip 
resistance. These patch-clamp electrodes were filled with internal solution contained in millimolar: 126 
potassium gluconate, 8 NaCl, 0.2 EGTA, 10 HEPES, 3 Mg2ATP, 0.3 GTP, and biocytin (Sigma; 0.2%), for 
subsequent neuron morphology analysis (pH = 7.2; 290 mosM) (Ambrogini et al. 2004; Betti et al. 2011).The 
electrode resistance in the bath ranged from 3 to 5 MΩ; the junction potential between internal and external 
solutions was not corrected. Somas to be recorded were identified in CA1 pyramidal cell layer based on their 
typical shape using an Axopatch-200B amplifier (Axon Instruments, USA) and WinWCP software 
(Strathclyde electrophysiology software whole cell analysis V 3.2.9, John Dempster, University of Strathclyde, 
UK). Resting membrane potential (RMP), input resistance (IR), capacitance (C) and cell excitability were 
determined as following described. Cell access was obtained in the voltage clamp mode and RMP was 
measured immediately upon break-in. Input resistance and capacitance were calculated in response to a 100-
ms, 5-mV hyperpolarizing pulse. In order to evaluate cell excitability, membrane potential in response to 
depolarizing current pulses (10 pA steps) was measured; if RMP was different from -70 mV, a holding current 
was delivered to bring the membrane potential to approximately -70 mV before the delivery of current pulses 
(Ambrogini et al. 2004). The amplitude and shape of the first elicited action potential, and the relationship 
between depolarizing injected current and percent of cell that elicit action potential were evaluated. The 
Afterhyperpolarization (AHP) was triggered using a depolarizing current step of 1 s able to induce maximum 
firing rate. A bipolar stimulating electrode pulled from theta capillary (World Precision Instruments) and filled 
with ACSF solution was placed in the stratum radiatum approximately 300 µm from the recorded cell. 
Postsynaptic potentials (PSPs) were recorded in current clamp mode and were evoked with an interstimulus 
frequency of 0.033 Hz. Stimulus intensity was adjusted at the lowest intensity (ranging from 100 to 200 µA) 
that evoked the maximal response. During PSC recordings, cells were held at a membrane potential of -70 mV, 
if not otherwise specified (Ambrogini et al. 2004; Betti et al. 2011). Tiple stimuli with an interstimulus interval 
of 50 ms were delivered every 20 s to the Schaffer collateral inputs and the amplitude of the three excitatory 
postsynaptic potentials was measured. In order to evaluate the effect of prenatal Cr supplementation on resting 
membrane potential, we considered RMP of all neurons and recordings were rejected only if the initial series 
resistance was >30 MΩ, if the series resistance measured at the end of the experiment had changed (±5 MΩ) 
or if DC offset exceeded 5 mV after withdrawal from the cell. 
 
4.2.3 Morphological analysis 
The same slices used for performing patch-clamp recordings, in which neurons were filled by the 
recording electrode with biocytin, were fixed with paraformaldehyde (4% PFA in PBS; Sigma-Aldrich, Italy) 
overnight at room temperature. Then, after several rinses with PBS, slices were incubated with streptavidin-
conjugated CY3 (Amersham, Italy; 1:500 in 0.01 M phosphate buffer saline-PBS, pH 7.4, containing 0.1% 
Triton X-100) overnight at room temperature; afterwards, slices were rinsed several times in PBS and mounted 
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on slides by antifading medium (Vector, DBA, Italy). Morphological reconstruction of each labeled pyramidal 
cell was performed using Leica TCS-SL confocal microscope, equipped with Argon and He/Ne laser sources. 
Morphological analysis was carried out on neurons without clear dendritic cutting at the slice surface. The total 
length of basal and apical dendritic trees of CA1 pyramidal cell was assessed using the image analysis software 
NeuronJ. Sholl concentric ring analysis was applied to evaluate dendritic tree complexity; concentric rings 
were superimposed to reconstructed cells and dendritic crossings were counted along both the basal (negative 
number) and apical (positive number) dendrites (Betti et al. 2011). 
 
4.2.4 Calcium Imaging 
Calcium imaging recordings in whole-cell configuration were performed at RT and the experiments 
were carried out under visual guidance using a Zeiss Axioskop microscope (Carl Zeiss International, Italy) 
equipped with a 40X water immersion objective and the Orca Flash 4.0 CCD camera (C11440, Hamamatsu, 
Japan). All recordings were performed on CA1 pyramidal neurons using an Axopatch-200B amplifier (Axon 
Instruments, USA) and WinFluor software (Strathclyde Imaging Software V 3.8.7, John Dempster, University 
of Strathclyde, UK). Patch electrodes were filled with an intracellular solution containing in millimolar: 126 
potassium gluconate, 8 NaCl, 10 HEPES, 3 Mg2ATP, 0.3 GTP (pH = 7.2; 290 mosM), and Fluo-4 
Pentapotassium Salt (100µM, Sigma), used for evaluating cellular calcium changes.  
Fluorescence images (600 X 600 pixels) were acquired at 10Hz frequency using a FITC excitation 
filter of 450-490 nm and fluorescence values were expressed as ΔF/F where F is the fluorescence at resting 
condition: the ROI (10 X 10 pixels) was placed on cell body and the background fluorescence was sampled in 
a region far from the loaded cell.  We minimized the photobleaching illuminating the slice with minimal light 
intensity. Fluorescence evaluation started immediately after break-in. During the loading phase F0 and the 
calcium transient in response a single action potential has been monitored: the single action potential was 
evoked in current clamp mode every 30 s by means of brief current pulse (2 ms) and the neurons were held at 
about -70 mV to avoid spontaneous action potentials. The steady-state was reached after about 15 minutes. 
Moreover, once the cells were full loaded with Fluo-4, fluorescence changes in response to high frequency 
stimulations (20-100 Hz, 600 ms) were evaluated. 
In each neuron unperturbed calcium transient, intracellular calcium concentration at resting condition 
[Ca2+]0 and during a single action potential Δ[Ca2+]AP were calculated according to Maravall et al. 2000. 
Calcium concentration was obtained using equation 1: 
 
∆[𝐶𝑎2+]
𝐾𝑑
=
𝐹𝑚𝑎𝑥
𝐹0
(1 − 𝑅𝑓
−1)
∆𝐹/𝐹
((∆𝐹/𝐹)𝑚𝑎𝑥 − ∆𝐹/𝐹) ∙ (∆𝐹/𝐹)𝑚𝑎𝑥
 
           (1) 
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where, Δ[Ca2+] is the transient in calcium concentration, Kd is the Fluo-4 dissociation constant 
(345 nM), Fmax is the fluorescence measured at saturation, F0 is the fluorescence during resting condition, Rf is 
the dynamic range of the indicator (we considered a value of 85 as reported for Fluo-4 in Maravall et al. 2000), 
ΔF/F is the rise in fluorescence divided by the resting fluorescence, (ΔF/F)max is the ΔF/F at saturation. Fmax 
was measured in every cell using high frequencies action potentials trains (from 20 to 100 Hz) to obtain 
maximal ΔF/F values. 
The calcium concentration at resting condition [Ca2+]0 was determined using equation 2: 
[𝐶𝑎2+]0
𝐾𝑑
=
1 − 𝑅𝑓
−1
(∆𝐹/𝐹)𝑚𝑎𝑥
− 𝑅𝑓
−1 
(2) 
The buffer capacity of the indicator (KB) was calculated using equation 3: 
𝐾𝐵 =  
𝐾𝑑 × [𝐵]𝑇
(𝐾𝑑 + [𝐶𝑎2+]0) × (𝐾𝑑 + [𝐶𝑎2+]𝑝𝑒𝑎𝑘)
 
(3) 
where [B]T is the Fluo-4 concentration (in nM) and [Ca2+]peak is the calcium concentration at the peak 
of the calcium transient. 
In both experimental groups the endogenous buffer capacity (KS) was evaluated back-extrapolating 
the relationship between the reciprocal of calcium transient amplitude during a single action potential 
(1/Δ[Ca2+]AP) and the exogenous buffer capacity (KB). The data obtained were fitted with a straight line and 
the intercept of this line with the x-axis provide an estimation of endogenous buffer capacity (KS = -(1 + x 
intercept)). 
 
4.2.5 Behavioral experiments: Morris Water Maze 
P60-70 CTRL and TREAT male rats (n = 6) were tested for spatial learning using the paradigm of 
Morris Water Maze. The apparatus consisted of a black circular swimming pool 1.65 m wide and 60 cm high, 
half-filled with water at temperature of 21 ± 1°C, in which an escape black platform 10 cm in diameter was 
placed, submerged 1.5 cm below the water surface and kept in the same position at 15 cm from pool wall (Betti 
et al. 2011). To guide rat escape behavior in locating the goal (platform), three different extramaze cues were 
used. To accustom the rat to the water, a pretraining session without platform was carried out. In this session 
the swimming speed of rats was also evaluated and it resulted not different between groups. Then, the training 
protocol was applied consisting in two sessions per day (8 a.m. and 2 p.m.) of four trials each (60 s with inter-
trial time of 60 s), over 4 consecutive days, for a total of 7 sessions. The time taken to reach the platform 
(escape latency) and the path length covered by the rats to get to the platform were recorded (Video tracking 
50 
 
system; Smart-BS, 2biological Instruments, Italy) and considered as parameters to evaluate learning. 
Moreover, in order to obtain a more reliable measure of learning, the day after the end of training, the rats 
performed the probe task by removing the platform from the pool and tracking the swim-path for 1 min. To 
evaluate the result of this test, the maze was virtually divided in four quadrants, one of which was centered on 
the position formerly occupied by the platform (goal quadrant); the time spent in the goal quadrant and in the 
others was calculated.  
 
4.2.6 Statistical analysis 
Data were expressed as mean ± SEM. Differences between the experimental groups were statistically 
evaluated by appropriately applying Student’s t-test or  square or Two-Way repeated measures ANOVA 
followed by Sidack’s post hoc test. The relationship between fEPSP slope and fiber volley amplitude was 
evaluated using linear regression. For all analyses the significance threshold was established at p = 0.05. 
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4.3 Results 
The ponderal growth curves of pregnant rats supplemented with Cr and of control were not different 
(data not shown). Furthermore, Cr supplementation did not affect the survival rate, weight of the pups at birth 
and litter size, and no evident teratogenic effect was observed in TREAT offspring. Lactating pups showed no 
significant intergroup differences in ponderal growth throughout the considered experimental period (data not 
shown); the timing of major maturational steps, i.e. hair coat development, eye opening and onset of movement 
control did not show differences between groups. 
 
4.3.1 Field potential recordings at P14-21 
Maternal Cr supplementation did not improve the probability of the epileptiform activity induction in CA1 
of the offspring at P14-21 after perfusion with synaptic inhibition blockers, bicuculline methiodide and 
4-Aminopyridine. The epileptic threshold was comparable in both groups due to a similar latency of the first 
interictal event and frequency of interictal events, as shown in Fig. 8 and Fig. 9, respectively.   
 
 
 
 
Fig. 8. Maternal creatine supplementation did not increase the epileptiform activity induction in CA1. In this 
graph it is shown the first interictal event latency recorded in hippocampal slices of control (CTRL, n = 8) 
and creatine supplemented group (TREAT, n = 6). The time between the perfusion of slices with bicuculline 
methiodide and 4-aminopyridine and the first interictal event was similar in both groups (CTRL: 226.65 ± 
53.65 s; TREAT: 249.18 ± 89.41 s). 
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-4.3.2 Whole-cell analysis at P60-70 
Electrophysiological characteristics of CA1 pyramidal neurons were recorded in whole-cell at P60-70. 
Membrane passive properties (IR and C) and resting membrane potential (RPM) of CA1 pyramidal cells were 
not significantly different in the TREAT group compared to the CTRL group (Table 1).  
 
 
 
 
Table 1. Electrophysiological characteristics of CA1 pyramidal neurons: 
membrane passive properties (IR and C) and resting membrane potential 
(RPM). 
 
 
Following, the neuronal firing evoked by somatic injection of increasing steps of depolarizing currents 
was investigated (Fig. 10A), and results demonstrated that CA1 neurons of offspring born from supplemented 
 Number RPM (mV) IR (MΩ) C (pF) 
CTRL 25 -67.2 ± 2.9 140.9 ± 7.8 183.4 ± 10.4 
TREAT 28 -63.1 ± 2.9 137.9 ± 8.8 171.3 ± 9.0 
 
Fig. 9. Frequency of interictal events in slices perfused with bicuculline methiodide and 4-aminopyridine. Field potential 
recordings in hippocampal slices showed no significant difference in the number of interictal events for each minute following the 
perfusion with synaptic inhibition blockers between both groups. CTRL, n = 8 slices; TREAT, n = 6 slices. 
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rats had a greater, but not significant enhancement of action potentials frequency in comparison to the control 
group (Fig. 10B). 
 
 
 
 
 
Fig. 10. Action potential frequency (Hz) following increasing step currents. (A) Example of increasing steps of depolarizing 
currents applied to CA1 neurons soma (1 s, 0-400 pA). (B) Number of action potential during incremental depolarizing 
step. TREAT neurons showed a tendency to have higher action potential frequency compared to controls. CTRL, n = 25 
neurons; TREAT, n = 22 neurons. 
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However, although not significant, there was a tendency in TREAT cells to exhibit higher excitability 
during step by step incremental stimulation current, and this was confirmed by analyzing the percentage of 
neurons that expressed action potentials at different current injections (Table 2). In particular, using a 
physiological range of stimulation (150 pA), TREAT neurons showed a significantly higher probability to 
generate action potentials (91 vs. 64%, p<0.05, Table 2). In addition, the complete excitability (100% of 
neurons expressing action potentials) was reached using a lower step of current intensity in Cr treated group 
(200 pA vs. 350 pA, Table 2).  
 
 
 
 
 
 
 
 
Table 2. Percentage of neurons that expressed action potentials 
at different current injections. Higher number of TREAT 
neurons showed action potentials after a physiological range of 
stimulation (91 vs. 64%, *Student’s t-test: p < 0.05) and reached 
complete excitability at lower step of current intensity (CTRL: 
350 pA; TREAT: 200 pA). 
 
Then, analyzing the input resistance (IR) in these cells, it could be observed that neurons from both 
groups with higher IR generated action potentials with lower stimulation intensity (<150 pA). Interestingly, 
neurons from CTRL group generating action potentials with current steps greater that 150pA showed a 
significantly lower IR compared to the CTRL neurons generating action potentials with less amount of 
stimulation (164.91 ± 10.78 MΩ vs 122.11 ± 8.12 MΩ, p<0.05, Fig. 11), while there was no difference in the 
TREAT group, that showed tendentially higher IR with stimulation higher than 150 pA compared to the control 
group (Fig. 11). This might explain why lower stimulations were sufficient to excite the 100% of TREAT cells 
compared to control.  
 
 
 
pA % CTRL % TREAT 
0 0 0 
50 12 18 
100 44 50 
150 64 91 *p<0.05 
200 88 100 
250 92 100 
300 96 100 
350 100 100 
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Examining the first action potential elicited by incremental current injections, the action potential 
waveform was similar in both groups (Fig. 12A). This was confirmed by no significant differences in 
characteristic measures of the action potential, namely the action potential threshold, half-width, rate of rise 
and T90% (Table 3). However, cells from the TREAT group showed a significantly reduced action potential 
amplitude (110.2 ± 3.9 vs. 118.6 ± 2.4 mV, p < 0.05, Fig. 12B).  
 
Table 3. Action potential measures. There were no differences in threshold (mV), half-width (ms), rate of rise (mV/ms), 
and T90% (ms) between CTRL and TREAT neurons. 
 
 
 
 Number Threshold (mV) Amplitude (mV) Half-Width (ms) Rate of Rise 
(mV/ms) 
T90% (ms) 
CTRL 25 54.0 ± 1.5 118.6 ± 2.4 1.7  ±0.1 310.5 ± 15.8 2.6 ± 0.1 
TREAT 28 55.6 ± 1.3 110.2 ± 3.9 1.8 ± 0.0 269 ± 19.0 2.6 ± 0.1 
 
Fig. 11. Input resistance (IR) in CA1 neurons at different current injections. IR was higher in neurons that generated action potentials 
at lower stimulation intensity (<150 pA) compared to stimulation greater than 150 pA in both groups. Significant difference was 
observed in CTRL group, between neurons that generated action potentials at current step lower than 150 pA and neurons that generated 
action potentials with higher stimulation (164.91 ± 10.78 MΩ vs. 122.11 ± 8.12 MΩ, Two-way ANOVA, *Sidack’s post hoc: p < 
0.05). CTRL, n = 25 neurons; TREAT, n = 22 neurons. 
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Fig. 12. First action potential elicited by incremental current injections. (A) Action potential waveform similar 
in both groups. (B) Action potential amplitude significantly lower in TREAT neurons compared to CTRL 
neurons. Values are expressed as mean ± SEM. *Student’s t-test: p < 0.05. CTRL, n = 25 neurons; TREAT, n = 
28 neurons. 
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Furthermore, we verified how many neurons showed AHP at maximum action potential frequency. 
As shown in Fig. 13B, greater number of TREAT cells exhibited AHP compared to CTRL group (12 vs. 48%, 
*p < 0.05).  
 
 
 
 
 
 
Fig. 13. (A) Example of afterhyperpolarization (AHP) recorded during step currents that induced the maximum firing of 
action potentials. (B) Percentage of neurons that showed AHP. A significantly reduced number of TREAT neurons showed 
AHP at the end of the current step that generated the maximum action potentials firing. * square test: p < 0.05. CTRL, n 
= 25 neurons; TREAT, n = 25 neurons. 
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Moreover, evoked synaptic response (excitatory postsynaptic potential, EPSP, and inhibitory 
postsynaptic potential, IPSP) amplitude were not significantly different between CTRL and TREAT group 
(Fig. 14). However, it is important to note that TREAT group tended to have a lower EPSP amplitude (p = 
0.08) compared to control, suggesting a lower synaptic response. In addition, triple pulse facilitation was 
similar in both group (Fig. 15), suggesting that the probability of neurotransmitter release from synaptic 
terminals was not affected by maternal Cr supplementation. Taking together, these results showed a reduced 
basal synaptic transmission in the TREAT group compared to control. 
 
 
Fig. 14. Postsynaptic potential (ESPS and IPSP) amplitude. (A) Example of postsynaptic response recorded after 
stimulation of Schaffer collaterals. (B) EPSP and IPS amplitude. TREAT neurons tend to have reduced EPSP 
amplitude. Student’s t-test: p = 0.08). CTRL, n = 22 neurons; TREAT, n = 17 neurons. 
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Fig. 15. Excitatory postsynaptic potential recorded applying triple pulse. (A) Example of triple stimuli delivered to the 
Schaffer collaterals that induce closed EPSP. (B) EPSP amplitude during triple pulse similar in both groups. 
60 
 
4.3.3 Field potential recordings at P60-70 
High frequency stimulation (HFS) of the Schaffer collaterals, applied after a 15 minutes baseline, 
induced a robust LTP in both groups. In slices from TREAT adult rats, after an initial depression, the fEPSP 
was increased and stabilized at higher values in comparison to the control group at least up to 40 min post 
HFS, suggesting an enhanced LTP maintenance (Fig. 16). This finding indicates that Cr supplementation 
during fetal life positively affected LTP of CA1 neurons of adult rats, confirming the results previously 
obtained in pups at P14-21 (Sartini et al. 2016).  
 
 
 
Fig. 16. Maternal creatine supplementation is associated with LTP improvement in CA1 neurons of adult rats. (A) fEPSP 
recorded during baseline and after high frequency stimulation; ( ) Slopes of fEPSPs. (B) Slope (between 10% and 80% 
of max) of the fEPSP was analyzed as measures of synaptic strength; values were normalized to the mean value obtained 
over the last 15 minutes of baseline period and express as a percentage of this baseline value. TREAT neurons exhibited 
a greater LTP compared to controls; Two-way ANOVA: F(1,25) = 4.886, p = 0.037. CTRL, n = 11 slices; TREAT, n = 
16 slices. 
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Then, postsynaptic excitability was tested by input/output curves, in which the fEPSP slopes were 
measured in response to single electrical stimuli of increasing magnitude. In Fig. 17, the ratio between the 
amplitude of the presynaptic fiber volley (input) and the slope of the postsynaptic fEPSPs (output) were plotted. 
It can be observed that neurons of TREAT group showed a significantly higher fiber volley amplitude and a 
lower fEPSP slope compared to the CTRL neurons, suggesting a greater number of activated synapses but 
with reduced output intensity. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17. Input/output curves. The fEPSP slopes vs. increasing presynaptic fiber volley amplitudes were plotted. Data were 
fit to a linear regression. The slope obtained in rats born by dams supplemented with creatine (0.87 ± 0.08, r2 = 0.99) was 
significantly different (p < 0.01) compared to control rats (1.23 ± 0.09, r2 = 0.98). CTRL, n = 11 slices; TREAT, n = 16 
slices. 
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4.3.4 Morphological analysis 
In the previous study, we found that maternal Cr supplementation affects cell morphology in rats at 
P14-21 (Sartini et al. 2016). In particular, CA1 pyramidal neurons filled with biocytin during whole-cell 
recordings from TREAT rats showed greater total dendritic length and global complexity of dendritic 
arborization. In order to evaluate whether these morphological modifications were maintained in adult life, 
dendritic length and complexity of dendritic arborization were analyzed also at P60-70 (two months after the 
end of Cr treatment). Results showed no differences in apical, basal, and total dendritic lengths between both 
groups. Moreover, Sholl analysis revealed that the number of basal and apical dendritic crossings along Sholl 
rings was similar in CA1 pyramidal cells of the two groups, suggesting that the morphological changes found 
at P14-21 are attenuated in adulthood.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18. Maternal creatine supplementation did not modify neuronal morphology in adult rats. (A) An 
example of CA1 pyramidal neuron processed for biocytin detection and reconstructed by confocal 
microscope, on which was carried out the morphological analysis. (B) Apical, basal, and total dendritic 
length of CA1 neurons. Values are expressed as mean ±SEM. No significant difference in dendritic length 
between both groups. CTRL: n=16 neurons; TREAT: n=13 neurons). Bar: 50 μm. 
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Fig. 19. Maternal creatine supplementation did not affect neuronal morphology in adult rats. (A) An example of CA1 pyramidal 
neuron processed for biocytin detection and reconstructed by confocal microscope, on which concentric Scholl rings from the 
soma and dendritic crossings (DC) were drawn; (B) Scholl analysis plot showing numbers of dendritic crossings along the Scholl 
rings as a function of distance from soma. Distributions of both basal and apical dendritic crossings did not result in significant 
differences between the two groups using Two-way ANOVA (basal: F(1,27) = 1.662, p = 0.21; apical: F(1,27) = 0.4699, p =0.50). 
CTRL: n=16 neurons; TREAT: n=13 neurons). Bar: 50 μm. 
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4.3.5 Morris Water Maze 
Analysis of data recorded during performances of CTRL and TREAT rats tested for spatial learning 
were collected in Fig. 20, Fig. 21. The time elapsed and the distance travelled to reach the hidden platform 
decreased over the sessions in both groups, indicating that the rats progressively became more efficient at 
locating the platform, thus escaping the water by learning the position of the platform relative to the visual 
cues (Fig. 20). However, comparing the learning curves between groups, there were no differences in the time 
(escape latency) and path length to reach the platform (Fig. 20).  
 
 
 
 
 
Fig. 20. Spatial learning tested in Morris water maze is similar in both groups. (A) Escape latency evaluated for each trial 
of every session; each point represents the mean value ± SEM of all animals used. (B) Path length measured for each trial 
of every session; each point represents the mean value ± SEM of all animals used. No differences in escape latency and path 
length in both groups. TREAT: treated rats (n = 6 from different litters); CTRL: control rats (n = 6 from different litters). 
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Moreover, no difference was found also in probe test, in which rats from both groups spent similar 
time in each quadrant, especially in the goal quadrant (5) (Fig. 21).   
 
 
 
 
 
Fig. 21. Water Maze probe test, performed the day after the end of training, assessed as permanence time (s) of the animal 
in the goal quadrant (5), and in the other quadrants shown in the schematic draw of the pool. Values were expressed as 
mean ± SEM. During the one-minute probe test, adult rats from different TREAT and CTRL litters spent similar time in 
the goal quadrant (5) and in each quadrant. TREAT: treated rats (n = 6 from different litters); CTRL: control rats (n = 6 
from different litters). 
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4.3.6 Intracellular calcium dynamics 
No differences were found in resting Ca2+ concentrations ([Ca2+]0, endogenous total buffering capacity 
(Ks) (Fig. 22), and in calcium concentrations involved during a single action potential (Fig. 23A) evoked in 
CA1 neurons of the two groups. However, the recordings of Ca2+ concentration transients by Fluo-4 intensity 
revealed a significantly lower increase from resting values in neurons of Cr treated group, when stimulated at 
20 Hz, a range of frequency easily reachable during the physiological hippocampal neuron activity (Fig. 23B). 
 
 
 
 
Fig. 22. Maternal creatine supplementation does not influence the resting Ca2+ concentrations ([Ca2+]0, 
endogenous total buffering capacity (Ks). (A) Resting calcium concentration similar in CA1 pyramidal 
neurons of both groups. CTRL = 51.53 ± 7.77 vs. TREAT = 46.46 ± 4.02 nM. (B) Endogenous buffer 
capacity does not change with creatine supplementation during pregnancy. The slope obtained in rats born 
by dams supplemented with creatine was not different (p = 0.84) compared to control rats. Ks is represented 
by the x-intercept when y=0; Ks CTRL = 92.76; Ks TREAT = 114.2; CTRL n = 28 neurons; TREAT n = 
36 neurons. 
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Fig. 23. Ca2+ concentration transient by Fluo-4 intensity during neuronal activity. (A) Ca2+ concentration transient 
during a single action potential did not differ between TREAT and CTRL neurons. (B) Maternal creatine 
supplementation affected calcium concentration transient elicited by 20 Hz stimulation. The ([Ca2+]0 increase was 
significantly lower in TREAT cells compared to controls. Two-way ANOVA: F(1,11) = 4.988, p = 0.047, *Sidack’s 
post hoc, p < 0.05 
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4.4 Discussion  
4.4.1 Epileptic Threshold 
In this study, the effects of maternal Cr supplementation in CA1 pyramidal neurons of rat progeny was 
investigated. Due to a higher neuronal excitability and an enhanced hippocampal output found at P14-21 in 
previous work (Sartini et al. 2016), the risk of an epileptogenic focus has been evaluated in this study through 
inducing of spontaneous epileptiform-like discharges and analysis of the epileptic threshold at P14-21. This 
experiment was conducted because an area characterized by high excitability situated in a network in which 
the inhibitory charge is not completely developed (Ko et al. 2015) could enhance the probability of an 
epileptogenic focus establishment, especially when this condition occurs together with other inducing factors, 
such as high body temperature (DellaBadia et al. 2004). However, in other experimental models, although such 
models are not properly comparable to the design used in this study, Cr has rather been reported to be 
neuroprotective and to prevent seizures. Indeed various studies have shown (Ireland et al. 2008, 2011; Cannata 
et al. 2010; Ellery et al. 2013) that maternal Cr administration protects the fetal CNS and, in developing rats, 
suppresses seizures caused by hypoxia (Holtzman et al. 1998). In accordance with this evidence, our 
experiments demonstrated that maternal Cr supplementation does not improve the probability of epileptiform 
activity induction in CA1 of offspring at P14-21 after blocking of inhibition and enhancement of the 
excitability of the circuit. Both groups showed similar epileptic thresholds, as the latency of the first interictal 
event and the frequency of interictal events were not significantly different. This suggests that the higher 
excitability of CA1 found in the previous study at P14-21 does not lead to increased risk of an epileptogenic 
focus, at least when using this experimental setting. 
 
4.4.2 Morphology of CA1 pyramidal neurons 
The effects of maternal Cr supplementation on morphological features of CA1 pyramidal neurons has 
been evaluated in adult rat progeny (P60-70). Our previous results obtained in pups demonstrated increased 
neuritic tree development, including greater total dendritic length and global complexity of dendritic 
arborization of CA1 pyramidal neurons of Cr treated group (Sartini et al. 2016). In this study, results showed 
no significant differences in apical, basal, and total dendritic lengths between both groups. Furthermore, Sholl 
analysis revealed that the number of basal and apical dendritic crossings along the Sholl rings was similar in 
CA1 pyramidal cells of the two groups, suggesting that the morphological changes found at P14-21 
progressively disappeared throughout the following weeks. These findings suggest that maternal Cr 
supplementation could anticipate the neuritic morphological development, as shown in P14-21 study, possibly 
because of a large availability of metabolic energy (Fukumitsu et al. 2015). This large metabolic energy would 
be able to favor cytoskeleton growth and dynamics, however this difference does not exist once neuron 
morphology has fully developed. 
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4.4.3 Intrinsic excitability 
Functional features of CA1 pyramidal neurons have been also investigated in adult rat progeny, and, 
interestingly, electrophysiological results suggest that some fundamental functional changes found twenty days 
after birth (Sartini et al. 2016) could be detected also in adulthood, namely two months after the end of the 
maternal Cr supplementation. This might lead to a hypothesis that a number of mechanisms related to maternal 
Cr administration, which are triggered during fetal life, can be permanently operative in adult life. 
First, the RMP and passive properties (IR and C) found were typical of CA1 pyramidal neurons of 
adult rats (Staley 1994; Milior et al. 2016) without significant differences between the two groups (Table 1). 
Furthermore, following somatic injection of increasing steps of depolarizing currents, CA1 neurons of 
offspring born from supplemented rats showed a greater, but not significant, increase of action potential 
frequency compared to the control group (Fig. 10). Nevertheless, in analyzing this finding from a different 
point of view, and thus examining the percentage of neurons that expressed action potentials at different current 
injection intensities (Table 2), some peculiarities can be observed. In particular, using a physiological range of 
stimulation (150 pA), TREAT neurons showed a significantly higher probability to generate action potentials. 
In addition, complete excitability (100% of neurons expressing action potentials) was reached using a lower 
step of current intensity in the Cr treated group (Table 2). These results confirm an enhanced excitability, with 
TREAT neurons seeming to be more excitable for the reason that they are able to respond to lower stimulation 
intensity. 
The analysis of the input resistance (IR) of these cells, taking into account the Ohm law equation, V= 
R·I, might clarify why lower stimulations were sufficient to excite 100% of TREAT cells compared to control 
cells. In fact, it could be observed that CA1 neurons from both groups with higher IR generated action 
potentials with lower stimulation intensity (<150 pA). Interestingly, neurons from the CTRL group that 
generated action potentials with current steps greater that 150pA showed significantly lower IR compared to 
the CTRL neurons, which generated action potentials with less intensity of stimulation, while there was no 
difference in the TREAT group, which tended to show higher IR with stimulation higher than 150 pA when 
compared to the control group (Fig. 11). Despite the fact that there was no difference in spike threshold (Table 
3), the tendency of TREAT neurons to show greater IR compared to controls might suggest the existence of 
differences in passive ion channel expression and/or in their membrane trafficking, with the potential ability 
to increase membrane resistance and then the excitability of these neurons.  
 
4.4.4 Long Term Potentiation and Calcium Dynamics 
Considering the higher excitability found in whole-cell recordings, the CA3-CA1 pathway was 
studied. High frequency stimulation of Schaffer collaterals induced an increased LTP at P60-70 in CA1 
neurons of the Cr treated group in comparison to controls (Fig. 16), as in previous study at P14-21 (Sartini et 
al. 2016). Furthermore, only a small percentage of these neurons showed AHP following maximum action 
potential frequency (medium afterhyperpolarization; King et al. 2015; Fig. 13). Regarding this AHP, however, 
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it is important to clarify that it was not possible to analyze the common measures of AHP, namely the amplitude 
and the area, because only three TREAT neurons showed AHP. The higher LTP in the TREAT group might 
be explained by a combination between presynaptic and postsynaptic activity. In particular, even if maternal 
Cr supplementation does not increase the presynaptic probability of neurotransmitter release as shown in 
whole-cell recordings using the triple-pulse stimulation, it enhances the number of synapses, although more 
weakly activated, as shown in the fiber volley amplitude/fEPSP ratio (Fig. 17). Thus, a greater number of 
synapses characterized by lower strength in the TREAT group, together with a similar presynaptic probability 
of neurotransmitter release, might explain the increased LTP through greater synapsis associativity and 
cooperativity, which are conditions that typically trigger LTP in hebbian CA3-CA1 synapses. Furthermore, 
TREAT neurons showing higher IR (Fig. 11) favor generation of action potentials, suggesting an enhancement 
of postsynaptic activity.  
It is well known that inhibition of Ca2+ transients generated by the activity of voltage-gated L-channel 
(Disterhoft et al. 1996; Kumar and Foster 2002) and/or from intracellular stores (Kumar and Foster 2004) is 
able to reduce AHP via small-conductance Ca2+-gated K+ (SK) channels  (Adelman et al. 2012; Berkefeld et 
al. 2010). Since LTP induction is facilitated by AHP reduction, and AHP might be related to different calcium 
handling (Kumar and Foster, 2004), calcium homeostasis in these cells was measured. Specifically 
measurements were taken of resting Ca2+ concentration, endogenous total buffering capacity, and Ca2+ 
transient during single action potential and during firing. No differences were found in resting Ca2+ 
concentrations and endogenous total buffering capacity (Fig. 22). However, in the Cr treated group, a tendency 
to develop lower Ca2+ transients during single action potentials was recorded; this tendency becomes 
significantly different when stimulated at 20 Hz, a range of frequency easily reachable during physiological 
hippocampal neuron activity, confirming the results of the literature. On the other hand, this lower Ca2+ 
transient intensity could be also a sufficient condition to explain the lower action potential amplitude of the 
same group (Fig. 5), as well as the lower AHP. 
 
4.4.5 Spatial learning  
Although underlying mechanisms are poorly understood, early life events producing subtle 
modifications in brain maturation can induce persistent behavioral and cognitive problems (Cannon et al. 
2002), and the hippocampus, given its long-lasting period of maturation, may be especially vulnerable to early 
life events, such as stress (Fenoglio et al. 2006) or prenatal malnutrition (Morgane et al 2002). Thus, maternal 
Cr supplementation might affect some behavioral and cognitive tasks in the progeny. Considering that 
hippocampal LTP is thought to be one of the main mechanisms underlying learning processes, such as spatial 
learning, the Morris Water Maze, which is one of the hippocampus-dependent spatial learning tests for rodents, 
was used in this study. Adult rats of both groups showed similar performances in the Morris water maze; both 
groups of rats did acquire the task at the end of training because the time elapsed and the distance travelled to 
reach the hidden platform decreased over the sessions. However, there were no differences in time taken 
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(escape latency) or total path length to reach the platform (Fig. 20), which was also the case in the probe test 
(Fig. 21). These behavioral results are not consistent with the enhanced LTP found in the TREAT group and 
this might be due to various reasons. Firstly, the low number of animals used in the study (n=6 for each group) 
might have been partly responsible for the elevated variability found in both groups, although this amount was 
chosen to limit the use of animals in order to conform with the National Institute of Health Guide for the Care 
and Use of Laboratory Animals. Furthermore, spatial learning might depend not only upon LTP but also on 
other mechanisms (McNamara and Skelton 1993). Finally, even though several authors have suggested that 
hippocampal LTP might be the neuronal basis for hippocampus-dependent learning, this was not proven in a 
conclusive manner (D’Hooge and De Deyn 2001). Indeed, some studies demonstrated that Morris Water Maze 
learning was still possible in animals where LTP mechanisms were blocked, and that Morris Water Maze 
performance can be impaired when LTP is increased (Cain 1997). 
 
4.4.6 Possible mechanisms 
It is interesting to consider that the majority of these findings at P60-70 imply direct or indirect ion-
channel modulation by maternal Cr supplementation, likely initiated started during fetal life, and that the 
effects can be conserved long after birth. Mechanisms involved in this scenario are not the target of this thesis, 
and as such only speculations can be made in this regard. A number of previous in vitro and in vivo studies 
have reported the ability of Cr to modulate neurotransmitter receptors and ion-channels. For example, the 
activity of brain GABAA receptor is increased by intracerebroventricular Cr injection (Koga et al. 2005) and, 
in addition, Cr is known to interact with benzodiazepine site of these receptors (Ireland et al. 2011). 
Furthermore, the activation of adenosine A1 and A2 receptors by Cr provides an antidepressant effect (Cunha 
et al. 2015). Regarding ion channel modulation, Cr supplementation in vitro was seen to increase Na+ and K+ 
currents in spinal neurons (Sartini et al. 2012), possibly as a consequence of enhanced voltage gated ion-
channel expression or membrane translocation, and to also accelerate the expression of the mature form of 
voltage-gated ion channels in rat CA1 neurons (Sartini et al. 2016). In this context it is also important to 
consider that neuron gene expression can be influenced by Cr via BDNF modulation (Allen et al. 2015) and 
that BDNF/TrKb signaling was shown to regulate ion channel membrane trafficking via phosphoinositide 3-
kinase (PI3K)-protein kinase B (PKB/Akt) cascade (Duan et al. 2012). Considering all of this information 
together, results in this study suggest that Cr supplementation during fetal life, a critical period for neuronal 
development, can affect rat CA1 neuron features, potentiating excitability and LTP for an extensive duration, 
weeks after the termination of supplementation. 
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4.5 Conclusion 
Results from this experiment show that maternal creatine supplementation positively affects the 
morpho-functional features of CA1 pyramidal neuron of rat offspring. Some morpho-functional changes found 
in the creatine treated group in comparison to controls suggest an anticipation of neural development; other 
changes are maintained also in adulthood, two months after maternal creatine supplementation. In detail, the 
morphological modifications found two-three weeks after birth progressively disappear throughout the 
following weeks, suggesting that maternal creatine supplementation may anticipate the neuritic morphological 
development. Once fully developed, CA1 pyramidal neurons are similar in hippocampus of adult rats born 
from both supplemented and control dams. Electrophysiological results suggest that some fundamental 
functional changes found two-three weeks after birth (Sartini et al. 2016) could be identified also in adulthood. 
Thus, some mechanisms triggered during fetal life by maternal creatine administration can be permanently 
operative in adult life. It is this the case of the LTP. In fact, CA3-CA1 pathway of TREAT group shows a 
higher LTP maintenance in comparison to controls, likely related to a lower calcium transient during neural 
activity. This is an interesting finding considering that LTP is one of the main mechanisms underlying learning 
processes, thus, maternal Cr supplementation might improve behavioral and cognitive task in rat progeny 
through these permanent modifications. Furthermore, in our experimental setting Cr supplementation during 
pregnancy does not cause side effects in neonatal rats, because, despite of the higher excitability of CA1 found 
in the previous study (Sartini et al. 2016), it does not improve the risk of epileptiform activity induction in 
hippocampus of offspring at postnatal day 14-21. This finding might be encouraging to future human studies 
and to a possible use of Cr during pregnancy to prevent and treat CNS damage in case of pre-, peri-, and post-
natal hypoxic-ischemic events caused by premature birth or placental insufficiency (Dickinson et al. 2014a; 
Ellery et al. 2016). 
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